Quanome posts $664K loss, flags going-concern doubt
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Quanome Technologies, Inc. (QNME), which distributes pharmaceutical and medical products, reported revenue of $2,048,083 for the three months ended September 30, 2026, compared with $1,338,015 a year earlier. Gross profit was $1,098,651, versus $547,245. Net loss was $664,270, compared with $1,357,216; the 2025 figure included $655,618 in losses from discontinued operations. Loss from continuing operations was $664,270, versus $701,598.
Cash used in continuing operating activities was $2,841, compared with $2,886,862 in the 2025 quarter, while quarter-end cash was $669,954. Investing activities included a $3,763,200 advance payment for furniture and equipment; financing activities included $3,799,980 in proceeds from a related-party loan. Net loans receivable from third parties were $7,166,895 after an expected-credit-loss allowance of $2,267,309.
At September 30, 2026, accumulated deficit was $15,518,392. Management said ongoing operations depend on external financing, including loans, notes or additional equity financing if necessary, and there is no assurance sufficient funds can be secured. The company said these factors raise substantial doubt about its ability to continue as a going concern.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointRevenue was $2,048,083, compared with $1,338,015 in 2025.
- Moderate pointOperating cash used was $2,841, versus $2,886,862 in 2025.
- Minor pointContinuing-operations loss was $664,270, versus $701,598 in 2025.
Negative
- Major pointSubstantial doubt about going concern; accumulated deficit was $15,518,392 at September 30, 2026.
Filing Explained
At September 30, Quanome reported no convertible notes outstanding after repaying them during the quarter.
This 10-Q reports that Quanome increased authorized common shares from 200 million at
The company also reports that it repaid the convertible notes in full during the quarter, including accrued interest, and had no convertible notes outstanding on
Key Figures
Key Terms
going concern financial
allowance for expected credit losses financial
discontinued operations financial
contract liabilities financial
amortized cost financial
performance obligation financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What revenue did QNME report for the quarter ended September 30, 2026?
What was QNME’s net loss for the September 2026 quarter?
How does QNME plan to fund operations?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(Mark One)
For the quarterly period ended
or
For the transition period from to .
Commission File No.
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
(Address of principal executive offices) (Zip Code)
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol(s) | Name of Each Exchange on Which Registered | ||
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| ☒ | Smaller reporting company | ||
| Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes
As of the date of this report, the Registrant had
QUANOME TECHNOLOGIES, INC.
FORM 10-Q
For the Quarterly Period Ended September 30, 2026
INDEX
| Page | ||
| PART I. FINANCIAL INFORMATION | ||
| Item 1. | Financial Statements | |
| Condensed Consolidated Balance Sheets as of September 30, 2026 (unaudited) and June 30, 2026 | F-2 | |
| Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended September 30, 2026 and 2025 (unaudited) | F-3 | |
| Condensed Consolidated Statements of Changes in Shareholders’ Equity for the three months ended September 30, 2026 and 2025 (unaudited) | F-4 | |
| Condensed Consolidated Statements of Cash Flows for the three months ended September 30, 2026 and 2025 (unaudited) | F-5 | |
| Notes to Condensed Consolidated Financial Statements (unaudited) | F-6 | |
| Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 1 |
| Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 11 |
| Item 4. | Controls and Procedures | 11 |
| PART II. OTHER INFORMATION | 12 | |
| Item 1. | Legal Proceedings | 12 |
| Item 1A. | Risk Factors | 12 |
| Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 12 |
| Item 3. | Defaults Upon Senior Securities | 12 |
| Item 4. | Mine Safety Disclosures | 12 |
| Item 5. | Other Information | 12 |
| Item 6. | Exhibits | 13 |
| Signatures | 14 |
i
EXPLANATORY NOTE
As used in this Quarterly Report on Form 10-Q (this “Report”), unless otherwise indicated or the context otherwise requires, references to “Quanome,” “the Company,” “we,” “us” and “our” refer to QUANOME TECHNOLOGIES, INC. (formerly known as Lakeside Holding Limited) together with its consolidated subsidiaries.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Report contains certain statements related to future results, or states our intentions, beliefs, and expectations or predictions for the future, all of which are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements represent management’s expectations or forecasts of future events. Forward-looking statements are typically identified by words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “project,” “intend,” “plan,” “probably,” “potential,” “looking forward,” “continue,” and other similar terms, and future or conditional tense verbs like “could,” “may,” “might,” “should,” “will,” and “would.” You can also identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from either historical or anticipated results depending on a variety of factors. Forward-looking statements in this Form 10-Q may include, for example, statements concerning:
| ● | our future operating and financial performance, ability to generate positive cash flow and ability to achieve and sustain profitability; |
| ● | our competitive position; |
| ● | the sufficiency of our existing capital resources to fund our future operating expenses; |
| ● | the timing of the introduction of new solutions and services; |
| ● | the likelihood of success in and impact of litigation; |
| ● | our protection or enforcement of our intellectual property rights; |
| ● | our expectation with respect to securities, options and future markets and general economic conditions; |
| ● | our ability to keep up with rapid technological change; |
| ● | the impact of future legislation and regulatory changes on our business; and |
| ● | our anticipated use of proceeds from our initial public offering. |
Any or all of our forward-looking statements may turn out to be inaccurate, and there are no guarantees about our performance. The factors identified above are not exhaustive. We operate in a dynamic business environment in which new risks may emerge frequently. Accordingly, readers should not place undue reliance on forward-looking statements, which speak only as of the dates on which they are made. We are under no (and expressly disclaim any) obligation to update or alter any forward-looking statement that we may make from time to time, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws.
ii
QUANOME TECHNOLOGIES, INC.
INDEX TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
| Page | |
| Condensed Consolidated Balance Sheets as of September 30, 2026 (unaudited) and June 30, 2026 | F-2 |
| Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended September 30, 2026 and 2025 (unaudited) | F-3 |
| Condensed Consolidated Statements of Changes in Shareholders’ Equity for the three months ended September 30, 2026 and 2025 (unaudited) | F-4 |
| Condensed Consolidated Statements of Cash Flows for the three months ended September 30, 2026 and 2025 (unaudited) | F-5 |
| Notes to Condensed Consolidated Financial Statements (unaudited) | F-6 - F-41 |
F-1
QUANOME TECHNOLOGIES, INC. (FORMERLY KNOWN AS LAKESIDE HOLDING LIMITED)
CONDENSED CONSOLIDATED BALANCE SHEETS
AS OF SEPTEMBER 30, 2026 (UNAUDITED) AND JUNE 30, 2026
| As of September 30, 2026 (unaudited) |
As of June 30, 2026 |
|||||||
| ASSETS | ||||||||
| CURRENT ASSETS | ||||||||
| Cash | $ | $ | ||||||
| Accounts receivable, net of credit loss allowance of $ | ||||||||
| Prepayment, deposits and other receivables, net | ||||||||
| Inventories, net | ||||||||
| Right of return asset | ||||||||
| Loan receivable from third parties, net of credit loss allowance of $ | ||||||||
| Total current assets | ||||||||
| NON-CURRENT ASSETS | ||||||||
| Property and equipment at cost, net of accumulated depreciation | ||||||||
| Intangible assets, net | ||||||||
| Right-of-use operating lease assets, net | ||||||||
| Prepayment, deposits and other receivable, net | ||||||||
| Total non-current assets | ||||||||
| TOTAL ASSETS | $ | $ | ||||||
| LIABILITIES AND EQUITY | ||||||||
| CURRENT LIABILITIES | ||||||||
| Accounts payable | $ | $ | ||||||
| Accrued liabilities and other payables | ||||||||
| Current portion of obligations under operating leases | ||||||||
| Loan payable, current | ||||||||
| Contract liabilities | ||||||||
| Income tax payable | ||||||||
| Due to a related party | ||||||||
| Loan payable to a related party | - | |||||||
| Refund liabilities | ||||||||
| Convertible debts - current | - | |||||||
| Total current liabilities | ||||||||
| NON-CURRENT LIABILITIES | ||||||||
| Loan payable, non-current | ||||||||
| Obligations under operating leases, non-current | ||||||||
| Total non-current liabilities | ||||||||
| TOTAL LIABILITIES | ||||||||
| Commitments and Contingencies | ||||||||
| EQUITY | ||||||||
| Common stock, $ | ||||||||
| Subscription receivable | ( | ) | ( | ) | ||||
| Additional paid-in capital | ||||||||
| Statutory reserve | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Accumulated other comprehensive income | ||||||||
| Total equity | ||||||||
| TOTAL LIABILITIES AND EQUITY | $ | $ | ||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
F-2
QUANOME TECHNOLOGIES, INC. (FORMERLY KNOWN AS LAKESIDE HOLDING LIMITED)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025
(UNAUDITED)
| For the Three Months Ended September 30, |
||||||||
| 2026 | 2025 | |||||||
| (unaudited) | (unaudited) | |||||||
| Revenue | $ | $ | ||||||
| Cost of revenue | ||||||||
| Gross profit | ||||||||
| Operating expenses: | ||||||||
| Selling expenses | ||||||||
| General and administrative expenses | ||||||||
| (Reversal of) provision of allowance for expected credit loss on accounts receivable | ( | ) | ||||||
| Provision of allowance for expected credit loss on loan receivable | - | |||||||
| Total operating expenses | ||||||||
| Loss from operations | ( | ) | ( | ) | ||||
| Other income (expense) | ||||||||
| Other income, net | ||||||||
| Interest expense | ( | ) | ( | ) | ||||
| Total other income (expense) | ( | ) | ||||||
| Loss before income taxes | ( | ) | ( | ) | ||||
| Income tax expense | ||||||||
| Net loss from continuing operations | ( | ) | ( | ) | ||||
| Net loss from discontinued operation, net of tax provision: | - | ( | ) | |||||
| Net loss | ( | ) | ( | ) | ||||
| Other comprehensive loss: | ||||||||
| Foreign currency translation gain | ||||||||
| Comprehensive loss attributable to the Company | $ | ( | ) | $ | ( | ) | ||
| Basic and Diluted Net Loss per Common Share | ||||||||
| Continuing operations | $ | ( | ) | $ | ( | ) | ||
| Discontinued operations, net of tax | $ | - | $ | ( | ) | |||
| Total basic and diluted net loss per common share attributable to the Company | $ | ( | ) | $ | ( | ) | ||
| Weighted Average Number of Common Shares Outstanding – basic and diluted | ||||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
F-3
QUANOME TECHNOLOGIES, INC. (FORMERLY KNOWN AS LAKESIDE HOLDING LIMITED)
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025
(UNAUDITED)
| For The Three Months Ended September 30, 2025 | ||||||||||||||||||||||||||||
| Common Shares |
Amount | Additional Paid in Capital |
Accumulated deficit | Accumulated Other Comprehensive Income |
Statutory Reserves |
Total | ||||||||||||||||||||||
| Balance at June 30, 2025 | $ | $ | $ | ( | ) | $ | $ | $ | ||||||||||||||||||||
| Net loss for the three months ended September 30, 2025 | — | — | — | ( | ) | — | — | ( | ) | |||||||||||||||||||
| Statutory reserve | — | — | — | ( | ) | — | — | |||||||||||||||||||||
| Foreign currency translation gain | — | — | — | — | — | |||||||||||||||||||||||
| Common stock issued for consulting services | — | — | — | |||||||||||||||||||||||||
| Issuance of common shares upon exercise of Convertible note | — | — | — | |||||||||||||||||||||||||
| Issuance of common shares - Private placement | — | — | — | |||||||||||||||||||||||||
| Balance at September 30, 2025 (unaudited) | $ | $ | $ | ( | ) | $ | $ | $ | ||||||||||||||||||||
| For The Three Months Ended September 30, 2026 | ||||||||||||||||||||||||||||||||
| Common Shares |
Amount | Subscription Receivable |
Additional Paid in Capital |
Statutory Reserves |
Accumulated deficit |
Accumulated Other Comprehensive Income |
Total | |||||||||||||||||||||||||
| Balance at June 30, 2026 | $ | $ | ( | ) | $ | $ | $ | ( | ) | $ | $ | |||||||||||||||||||||
| Net loss for the three months ended September 30, 2026 | - | - | - | - | - | ( | ) | - | ( | ) | ||||||||||||||||||||||
| Statutory reserve | - | - | - | - | ( | ) | - | - | ||||||||||||||||||||||||
| Foreign currency translation gain | - | - | - | - | - | - | ||||||||||||||||||||||||||
| Balance at September 30, 2026 (unaudited) | $ | $ | ( | ) | $ | $ | $ | ( | ) | $ | $ | |||||||||||||||||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
F-4
QUANOME TECHNOLOGIES, INC. (FORMERLY KNOWN AS LAKESIDE HOLDING LIMITED)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025
(UNAUDITED)
| For the Three Months Ended September 30, |
||||||||
| 2026 | 2025 | |||||||
| (unaudited) | (unaudited) | |||||||
| Cash flows from operating activities: | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Less: Loss from discontinued operation, net of tax provision | - | ( | ) | |||||
| Net loss from continuing operations | ( | ) | ( | ) | ||||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation | ||||||||
| Amortization of intangible asset | ||||||||
| Lease expense of operating lease assets | ||||||||
| (Reversal of) Provision of allowance for expected credit loss on accounts receivable | ( | ) | ||||||
| Provision of allowance for expected credit loss on loan receivable | - | |||||||
| Amortization of discount and bond issuance cost | - | |||||||
| Change in deferred tax liability | - | ( | ) | |||||
| Interest income | ( | ) | ( | ) | ||||
| Stock-based compensation expense for consulting services | ||||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | ( | ) | ( | ) | ||||
| Note receivables | - | |||||||
| Inventories | ( | ) | ||||||
| Right of return asset | ( | ) | ||||||
| Prepayment, deposit and other receivable | ( | ) | ( | ) | ||||
| Accounts payable | ( | ) | ||||||
| Contract liabilities | ( | ) | ||||||
| Accrued expense and other payables | ( | ) | ||||||
| Interest paid on convertible note | ( | ) | - | |||||
| Due to a related party | - | |||||||
| Refund liabilities | ||||||||
| Income tax payable | ||||||||
| Operating lease liabilities | ( | ) | ( | ) | ||||
| Net cash used in operating activities from continuing operations | ( | ) | ( | ) | ||||
| Cash flows from investing activities: | ||||||||
| Advance payment for purchase of furniture and equipment | ( | ) | - | |||||
| Repayment of loans receivable from third parties | - | |||||||
| Net cash used in investing activities from continuing operations | ( | ) | - | |||||
| Cash flows from financing activities: | ||||||||
| Proceeds from loan from a related party | - | |||||||
| Repayment of loans | ( | ) | ( | ) | ||||
| Repayment of principal of convertible debt | ( | ) | ( | ) | ||||
| Repayment of equipment and vehicle loans | ( | ) | ( | ) | ||||
| Proceeds from a private placement | - | |||||||
| Advance to a third party | - | ( | ) | |||||
| Net cash provided by financing activities from continuing operations | ||||||||
| CASH FLOWS FROM DISCONTINUED OPERATION | ||||||||
| Operating activities | - | ( | ) | |||||
| Investing activities | - | ( | ) | |||||
| Financing activities | - | |||||||
| Net cash used in discontinued operation | - | ( | ) | |||||
| Effect of exchange rate changes on cash | ||||||||
| Net decrease in cash | ( | ) | ( | ) | ||||
| Cash, beginning of the period – continuing operation | ||||||||
| Cash, beginning of the period – discontinued operation | - | |||||||
| Total cash, beginning of the period | ||||||||
| Cash, end of the period | ||||||||
| Less: cash of discontinued operations | - | |||||||
| Cash, end of the period for continuing operations | $ | $ | ||||||
| SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: | ||||||||
| Cash paid for income tax | $ | $ | ||||||
| Cash paid for interest | $ | $ | ||||||
| NON-CASH ACTIVITIES | ||||||||
| Issuance of common shares in exchange for consulting service | $ | - | $ | |||||
| Convertible notes converted to common shares | $ | - | $ | |||||
| Property and equipment additions through loan payable | $ | - | $ | |||||
| Decrease in operating lease right-of-use assets and corresponding lease liabilities resulting from lease modifications | $ | $ | - | |||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
F-5
QUANOME TECHNOLOGIES, INC. (FORMERLY KNOWN AS LAKESIDE HOLDING LIMITED)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 1 — ORGANIZATION AND BUSINESS DESCRIPTION
Quanome Technologies, Inc. (formerly known as Lakeside Holding Limited) (the “Company”), is a holding company established on August 28, 2023 under the laws of the State of Nevada. The Company, acting through its subsidiaries, is primarily engaged in distribution of pharmaceutical and medical products.
As of September 30, 2026, the Company’s subsidiaries are as follows:
| Name | Date of Incorporation/ Acquisition | Jurisdiction of Formation | Percentage of direct/indirect Economic Ownership | Principal Activities | ||||
| Parent Company | ||||||||
| Quanome Technologies, Inc. (formerly known as Lakeside Holding Limited) | Parent | |||||||
| Subsidiaries/companies with ownership | ||||||||
| Sichuan Hupan Jincheng Enterprise Management Co., Ltd (“Sichuan Hupan”) | ||||||||
| Hupan Pharmaceutical (Hubei) Co., Ltd (“Hupan Pharmaceutical”) | ||||||||
| Smart Reserve Holding LTD | ||||||||
| Smart Reserve Inc | ||||||||
| Quantum Nexus Technologies Ltd | ||||||||
| XDT, INC. | ||||||||
| XDT US HoldCo, LLC | ||||||||
| XDT Infrastructure I, LLC | ||||||||
| XDT Infrastructure II, LLC |
F-6
QUANOME TECHNOLOGIES, INC. (FORMERLY KNOWN AS LAKESIDE HOLDING LIMITED)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of presentation and principles of consolidation
The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company’s annual report on Form 10-K for the year ended June 30, 2026.
In the opinion of the Company’s management, the unaudited interim condensed consolidated financial statements include all adjustments, which are only of a normal and recurring nature, necessary for a fair statement of the financial position of the Company as of September 30, 2026, and its results of operations and cash flows for the three-month period then ended. Operating results for the three months ended September 30, 2026 are not necessarily indicative of the results that may be expected for the fiscal year ended June 30, 2027
The accompanying unaudited condensed consolidated financial statements include the financial statements of Quanome Technologies, Inc. (formerly known as Lakeside Holding Limited) and its subsidiaries. All inter-company balances and transactions have been eliminated upon consolidation.
Going concern
The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the discharge of liabilities in the normal course of business for the foreseeable future.
As of September 30, 2026, the Company had an accumulated deficit of approximately $
These factors, among others, raise the substantial doubt regarding the Company’s ability to continue as a going concern. These unaudited condensed consolidated financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of these uncertainties. Management believes that the actions presently being taken to obtain additional funding and implement its strategic plan provide the opportunity for the Company to continue as a going concern.
F-7
QUANOME TECHNOLOGIES, INC. (FORMERLY KNOWN AS LAKESIDE HOLDING LIMITED)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)
Discontinued Operations
On May 15, 2026, the Company entered into a Share Purchase Agreement with an unrelated third party for the disposition of ABL Chicago (the “Transaction”) and the transaction was legally finalized on May 16, 2026.
Effective February 12, 2026, the buyer assumed substantive decision-making authority and operational control over the transferred business and obtained the rights to substantially all economic benefits and obligations associated with the ownership of the business. In addition, the Company no longer retained substantive continuing involvement in the operations of ABL Chicago.
Accordingly, the Company accounted for the Transaction as a disposal/deconsolidation effective February 12, 2026 in accordance with ASC 810-10-40-4.
The results of operations of ABL Chicago are included in “Loss from discontinued operations, net of tax provision” in the accompanying unaudited condensed consolidated statements of operations and comprehensive loss. For comparative purposes, all prior periods presented have been reclassified to reflect the classifications on a consistent basis (see Note 17).
Use of estimates and assumptions
In preparing the unaudited condensed consolidated financial statements in conformity with U.S. GAAP, management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. These estimates are based on information as of the date of the unaudited condensed consolidated financial statements. Significant accounting estimates required to be made by management include allowance for credit losses on account receivable and loan receivable from a third party, return liabilities, percentage of performance obligation completed at the reporting period, the measurements of convertible debts with accompanying warrants. The Company evaluates its estimates and assumptions on an ongoing basis and its estimates on historical experience, current and expected future conditions and various other assumptions that management believes are reasonable under the circumstances based on the information available to management at the time these estimates and assumptions are made. Actual results and outcomes may differ significantly from these estimates and assumptions.
Cash
Cash consists of unrestricted balances held with banks and deposits at banks or other financial institutions, which are available for withdrawal or use and have original maturities of three months or less. The Company maintains its bank accounts in the United States, which are insured by Federal Deposit Insurance Corporation (“FDIC”) at a limit of $
As of September 30, 2026 and June 30, 2026, the Company had approximately $
F-8
QUANOME TECHNOLOGIES, INC. (FORMERLY KNOWN AS LAKESIDE HOLDING LIMITED)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)
Accounts receivable, net
Accounts receivable are carried at the original invoiced amount less an estimated allowance for expected credit losses based on the probability of future collection. The Company reviews its accounts receivable on a periodic basis and makes general and specific allowances when there is doubt as to the collectability of individual balances. The Company grants credit to customers, without collateral, under normal payment terms. The Company estimates expected credit losses on accounts receivable using a loss-rate method. In estimating the allowance, the Company considers historical credit loss and collection experience, the aging of outstanding balances, customers’ payment histories and financial condition, current economic conditions, and reasonable and supportable forecasts of future economic conditions, when appropriate. Accounts receivable that are more than one year past due and other receivables identified as having elevated credit risk are evaluated individually for collectability. The Company writes off potentially uncollectible accounts receivable against the allowance for credit losses if it is determined that the amounts will not be collected. As of September 30, 2026 and June 30, 2026, the Company recorded the allowance of credit loss of $
Loan receivable from third parties and allowance for credit losses
Loans receivable from third parties are recorded at amortized cost, representing the principal amount and interest receivable outstanding net of any allowance for credit losses (see Note 5). The Company accounts for credit losses under ASC Topic 326, Financial Instruments—Credit Losses, which requires the immediate recognition of estimated credit losses expected to occur over the remaining life of the financial asset. The Company determines the allowance for credit losses by utilizing a Probability of Default (“PD”) and Loss Given Default (“LGD”) methodology. As of September 30, 2026 and June 30, 2026, the Company recorded an allowance for expected credit losses of $
Inventories, net
Inventories are stated at the lower of cost or net realizable value, using the first-in, first out (FIFO) method. Costs include the cost of pharmaceutical products. Any excess of the cost over the net realizable value of each item of inventories is recognized as a provision for diminution in the value of inventories. Net realizable value is estimated using selling price in the normal course of business less any costs to complete and sell products. As of September 30, 2026 and June 30, 2026, the Company did not record any inventory provision.
Property and equipment
Property and equipment are stated at cost less accumulated depreciation. The straight-line depreciation method is used to compute depreciation over the estimated useful lives of the assets, as follows:
| Useful life | ||
| Furniture and fixtures | ||
| Machinery equipment | ||
| Vehicles | ||
| Software | ||
| Leasehold improvement | Lesser of the lease term or estimated useful lives of the assets |
F-9
QUANOME TECHNOLOGIES, INC. (FORMERLY KNOWN AS LAKESIDE HOLDING LIMITED)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)
Property and equipment (cont.)
Expenditures for maintenance and repairs, which do not materially extend the useful lives of the assets, are charged to expense as incurred. Expenditures for major renewals and betterments which substantially extend the useful life of assets are capitalized. The cost and related accumulated depreciation of assets retired or sold are removed from the respective accounts, and any gain or loss is recognized in other income or expenses in the unaudited condensed consolidated statements of loss and other comprehensive loss.
Intangible Assets, net
Intangible assets consist primarily of business license acquired from asset acquisition. It grants the Company the right of selling and distributing pharmaceutical products and solutions in mainland China.
Intangible assets are stated at cost less accumulated amortization. The license is amortized using the straight-line method over the estimated useful economic life of
Accounts payable
Accounts payable primarily represent amounts due to suppliers for goods received in the ordinary course of business, payable within
Impairment of long-lived asset
Long-lived assets, including plant, property and equipment and intangible asset, are evaluated for impairment whenever events or changes in circumstances (such as a significant adverse change to market conditions that will impact the future use of the assets) indicate that the carrying amount may not be fully recoverable or that the useful life is shorter than the Company had originally estimated. When these events occur, the Company evaluates the impairment by comparing the carrying value of the assets to an estimate of future undiscounted cash flows expected to be generated from the use of the assets and their eventual disposition. If the sum of the expected future undiscounted cash flows is less than the carrying value of the assets, the Company recognizes an impairment loss based on the excess of the carrying value of the assets over the fair value of the assets. The Company reviews the impairment of its right-of-use assets and intangible asset consistent with the approach applied for its other long-lived assets. No impairment charge was recognized for the three months ended September 30, 2026 and 2025, respectively.
Related parties
The Company adopted ASC 850, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.
Leases
The Company evaluates the contracts it entered into to determine whether such contracts contain leases at inception. A contract contains a lease if the contract conveys the right to control the use of identified property, plant or equipment for a period of time in exchange for consideration. At commencement, contracts containing a lease are further evaluated for classification as an operating or finance lease where the Company is a lessee.
F-10
QUANOME TECHNOLOGIES, INC. (FORMERLY KNOWN AS LAKESIDE HOLDING LIMITED)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)
Leases (cont.)
Operating Leases
A lease for which substantially all the benefits and risks incidental to ownership remain with the lessor is classified as an operating lease. Operating leases are included in the line items right-of-use (ROU) asset, lease liabilities, current, and lease liabilities, non-current in the unaudited condensed consolidated balance sheet. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. For operating leases, the Company measures its lease liabilities based on the present value of the total lease payments not yet paid discounted based on the more readily determinable of the rate implicit in the lease or its incremental borrowing rate, which is the estimated rate the Company would be required to pay for a collateralized borrowing equal to the total lease payments over the term of the lease. The Company uses its incremental borrowing rate based on the information available at lease commencement date in determining the present value of lease payments. The Company measures ROU assets based on the corresponding lease liability adjusted for payments made to the lessor at or before the commencement date, and initial direct costs it incurs under the lease. The Company begins recognizing lease expense when the lessor makes the underlying asset available to the Company. Lease expenses for lease payments are recognized on a straight-line basis over the lease term.
For leases with lease term less than one year (short-term leases), the Company has elected not to recognize a lease liability or ROU asset on its unaudited condensed consolidated balance sheet. Instead, it recognizes the lease payments as expenses on a straight-line basis over the lease term. Short-term lease costs are immaterial to its unaudited condensed consolidated statements of operations and cash flows.
Fair value of financial instruments
ASC 820, “Fair Value Measurements” (ASC 820) and ASC 825, “Financial Instruments” (ASC 825), requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. It establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. It prioritizes the inputs into three levels that may be used to measure fair value:
| Level 1 — | Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities | |
| Level 2 — | Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. | |
| Level 3 — | Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. |
The carrying value of cash, accounts receivable, other receivables, loan receivable from third parties, accounts payable, convertible debts - current, other payables and accrued expenses and other current liabilities approximate fair value due to their short-term nature. For lease liabilities and loans payable, their carrying value approximate the fair value at the year-end, as the interest rates used to discount the host contracts approximate market rates. The Company noted no transfers between levels during any of the periods presented. The Company did not have any instruments that were measured at fair value on a recurring nor non-recurring basis as of September 30, 2026 and June 30, 2026.
F-11
QUANOME TECHNOLOGIES, INC. (FORMERLY KNOWN AS LAKESIDE HOLDING LIMITED)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)
Convertible debts
In accordance with ASC 470, Debt (“ASC 470”) the Company records its
In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. Under ASU 2020-06, the embedded conversion features are no longer separated from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives under Derivatives and Hedging (Topic 815), or that do not result in substantial premiums accounted for as paid-in capital. Consequently, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost, as long as no other features require bifurcation and recognition as derivatives. The guidance also requires the if-converted method to be applied for all convertible instruments. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted. Adoption of the standard requires using either a retrospective or a retrospective approach. The Company adopted ASU 2020-06 on July 1, 2024, using the modified retrospective method. The adoption of ASU 2020-06 did not have a material impact on the Company’s unaudited condensed consolidated financial statements and related disclosures.
Debt issuance costs
Direct and incremental costs and original issue discounts and premiums incurred in connection with the issuance of long-term debt are deferred and amortized to interest expense using the effective interest method or, if the amounts approximate the effective interest method, on a straight-line basis. All debt issuance costs are presented as a direct reduction of debt on the unaudited condensed consolidated balance sheets. Amortization of debt issuance costs and original issue discounts and premiums recognized as interest expense was $nil and $
Common stock warrants
The Company evaluates common stock warrants under ASC 815-40, Derivatives and Hedging—Contracts in Entity’s Own Equity. The Company assesses whether common stock warrants are freestanding financial instruments and whether they meet the criteria to be classified in shareholders’ equity, or classified as a liability. Where common stock warrants do not meet the conditions to be classified in equity, the Company assesses whether they meet the definition of a liability under ASC 815.
F-12
QUANOME TECHNOLOGIES, INC. (FORMERLY KNOWN AS LAKESIDE HOLDING LIMITED)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)
Revenue recognition
The Company adopted ASC Topic 606 “Revenue from Contracts with Customers” and all subsequent ASUs that modified ASC 606. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, the Company applies the following steps:
Step 1: Identify the contract (s) with a customer
Step 2: Identify the performance obligations in the contract
Step 3: Determine the transaction price
Step 4: Allocate the transaction price to the performance obligations in the contract
Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation
The Company generates revenue from distribution of pharmaceutical products. The Company did not elect any practical expedients upon adoption of ASC 606. Revenue recognition policies are as follows:
Revenue recognized from continuing operations during the three months ended September 30, 2026 and 2025 was from the following sources:
Revenue from distribution of pharmaceutical products
The Company generates revenue from the distribution of pharmaceutical and medical products. The Company orders products from the manufacturer, receives and carries the product at a designated warehouse, and delivers the product directly to its customers’ warehouses or designated locations. Revenue is recognized at a point in time when control of goods is transferred to the customers upon goods delivered to the customers and accepted by the customers.
Principal and agent considerations
In the Company’s distribution of pharmaceutical products business, the Company determined that in all of its major business activities, it serves as a principal rather than an agent within their revenue arrangements under the fact that the Company controls the goods before they are transferred to customers, bears inventory risk, and has discretion in establishing pricing. As a principal, the Company recognizes revenue on a gross basis within the unaudited condensed consolidated statements of operations and comprehensive loss.
Contract liabilities
Contract liabilities represent estimated advances received from customers. The contract liabilities are reported in a net position on a customer-by-customer basis at the end of each reporting period. Contract liabilities are recognized when the Company receives prepayment from customers resulting from purchase order. Contract liabilities will be recognized as revenue when the products are delivered. As of September 30, 2026 and June 30, 2026, the Company recorded contract liabilities of $
F-13
QUANOME TECHNOLOGIES, INC. (FORMERLY KNOWN AS LAKESIDE HOLDING LIMITED)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)
Refund liabilities and right of returned assets
Refund liabilities represent the estimated amount of consideration expected to be refunded to customers and are recorded at the time revenue is recognized. Refund allowances are recorded as a reduction in sales with corresponding refund liabilities, and the estimated cost of refunded inventory is recorded as a reduction to cost of sales and an increase of right of return assets. The estimate is based on historical refund patterns, current trends, and contractual terms. If actual results differ from the estimates, the Company revises its estimated refund liabilities accordingly. Each period end, the Company reviews and reassesses the adequacy of its recorded refund liabilities and adjusts the amount as necessary. As of September 30, 2026 and June 30, 2026, the Company recorded refund liabilities of $
Cost of revenues
In the Company’s distribution of pharmaceutical products business, cost of revenues primarily consists of cost of products, less discount and rebate.
Selling expenses
Selling expenses primarily include salaries expense, marketing expense of a system, entertainment expense and traveling expense of sales team engaged in developing potential customers and maintaining customer relationships and transportation cost for selling pharmaceutical products.
General and administrative expenses
General and administrative expenses primarily include salaries and staff benefits, amortization on intangible assets, depreciation on property and equipment, lease expenses of office premises, travelling and entertainment, bank charges, legal and professional fees, insurance expenses and other office expenses.
Employee defined contribution plan
Full-time employees of the Company in the PRC participate in a government-mandated multi-employer defined contribution plan pursuant to which certain pension benefits, medical care, unemployment insurance, employee housing fund and other welfare benefits are provided to them. Chinese labor regulations require that the Company make contributions to the government for these benefits based on government prescribed percentage of the employee’s salaries. The Company has no legal obligation for the benefits beyond the contributions. The total amount was expensed as incurred. For the three months ended September 30, 2026 and 2025, employee welfare contribution expenses amounted to approximately $
Value added tax (“VAT”)
Revenue represents the invoiced value of goods and service, net of VAT. The VAT is based on gross sales price and VAT rates range up to
F-14
QUANOME TECHNOLOGIES, INC. (FORMERLY KNOWN AS LAKESIDE HOLDING LIMITED)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)
Income taxes
Income tax expense is the total of the current year income tax due or refundable and the change in deferred tax assets and liabilities. Deferred tax assets and liabilities are the expected future tax amounts for the temporary differences between carrying amounts and tax bases of assets and liabilities computed using enacted tax rates. A valuation allowance, if needed, reduces deferred tax assets to the amount expected to be realized.
The Company accounts for uncertain tax positions in accordance with FASB ASC Topic No. 740, Accounting for Uncertainty in Income Taxes. A tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. As of September 30, 2026 and June 30, 2026, the Company did not have a liability for unrecognized tax benefits. It is the Company’s policy to include penalties and interest expense related to income taxes as a component of other expense and interest expense, respectively, as necessary. The Company’s historical tax years will remain open for examination by the local authorities until the statute of limitations has passed.
In December 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures”, which improves income tax disclosures. The amendments require the disclosure of specific categories in rate reconciliation and additional information for reconciling items that meet a quantitative threshold. The amendments also require disaggregated information about the amount of income taxes paid (net of refunds received), Income (or loss) from continuing operations before income tax expense (or benefit) and Income tax expense (or benefit) from continuing operations. The new guidance is required to be applied either prospectively or retrospectively. The Company adopted ASU 2023-09 effective July 1, 2025, using the prospective method. The adoption resulted in additional income tax disclosures but did not affect the recognition or measurement of income taxes in the Company’s unaudited condensed consolidated financial statements. See Note 15—Income Taxes.
Statutory reserves
The Company’s PRC subsidiaries are required to allocate at least
Comprehensive loss
Comprehensive loss consists of two components, net loss and other comprehensive loss. Other comprehensive loss refers to revenue, expenses, gains and losses that under GAAP are recorded as an element of equity but are excluded from net loss. Other comprehensive loss consists of a foreign currency translation adjustment resulting from the Company not using the U.S. dollar as its functional currencies.
F-15
QUANOME TECHNOLOGIES, INC. (FORMERLY KNOWN AS LAKESIDE HOLDING LIMITED)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)
Basic and diluted loss per share
The Company computes earnings per share (“EPS”) in accordance with ASC 260, “Earnings per Share” (“ASC 260”). ASC 260 requires companies with complex capital structures to present basic and diluted EPS. Basic EPS is measured as net income (loss) divided by the weighted average common shares outstanding for the period. Diluted EPS presents the dilutive effect on a per share basis of potential common shares (e.g., convertible securities, options and warrants) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. For the three months ended September 30, 2026 and 2025, the Company reported a net loss. As a result, all potentially dilutive securities, including the convertible debenture, were excluded from the calculation of diluted loss per share because their inclusion would have been antidilutive.
Foreign currency transactions
Our reporting currency is the U.S. dollar. The functional currency of our operations, except for Sichuan Hupan and Hupan Pharmaceutical, is the U.S. dollar. The functional currency of Sichuan Hupan and Hupan Pharmaceutical is the RMB. The assets, liabilities, revenues, and expenses of Sichuan Hupan and Hupan Pharmaceutical are remeasured in accordance with ASC 830. For the three months ended September 30, 2026 and 2025, assets and liabilities of Sichuan Hupan and Hupan Pharmaceutical are translated into U.S. dollars based upon exchange rates prevailing at the end of the period. Revenues and expenses of Sichuan Hupan and Hupan Pharmaceutical are translated at average exchange rates during the reporting period. The resulting translation adjustment is included in accumulated other comprehensive income.
The following table outlines the currency exchange rates that were used in creating the unaudited condensed consolidated financial statements in this report:
| September 30, 2026 | September 30, 2025 | |||
| Balance sheet items, except for equity accounts | US$ | US$ | ||
| Items in the statements of income and cash flows | US$ | US$ |
Commitments and contingencies
In the normal course of business, the Company is subject to contingencies, such as legal proceedings and claims arising out of its business, which cover a wide range of matters. Liabilities for contingencies are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated.
If the assessment of a contingency indicates that it is probable that a material loss is incurred and the amount of the liability can be estimated, then the estimated liability is accrued in the Company’s financial statements. If the assessment indicates that a potentially material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingency liability, together with an estimate of the range of possible loss, if determinable and material, would be disclosed.
Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the nature of the guarantee would be disclosed.
F-16
QUANOME TECHNOLOGIES, INC. (FORMERLY KNOWN AS LAKESIDE HOLDING LIMITED)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)
Concentrations and risks
a. Concentration of credit risk
The Company estimates credit losses over the contractual period in which the Company is exposed to credit risk via a contractual obligation to extend credit, unless that obligation is unconditionally cancellable by the Company. Assets that potentially subject the Company to significant concentration of credit risk primarily consist of cash, accounts receivable, note receivable, other receivable and loan receivable balance from third parties. The Company has designed their credit policies with an objective to minimize their exposure to credit risk.
The maximum exposure of such assets to credit risk is their carrying amounts at the balance sheet dates. The Company maintains majority of bank accounts in mainland China, where there is a RMB
The Company also has the bank accounts at financial institutions in the United States, where there is $
The Company has adopted a credit policy of dealing with creditworthy counterparties to mitigate the credit risk from defaults. The management team conducts credit evaluations of its customers, and generally does not require collateral or other security from them. The Company establishes an accounting policy to provide for allowance for credit loss based on the individual customer’s financial condition, credit history, and the future economic conditions. Except loan receivable from a third party and other receivable are monitored on an ongoing basis with the result that the Company’s exposure to impairment is not significant. As of September 30, 2026 and June 30, 2026, the Company recognized an allowance for credit loss of $
b. Foreign exchange risk
Our subsidiaries in PRC have functional currency in RMB. PRC subsidiaries’ expense transactions are denominated in RMB and their assets and liabilities are denominated in RMB. RMB is not freely convertible into foreign currencies. The value of the Chinese Yuan against the U.S. dollar is affected by the changes in China and United States economic conditions. We do not believe that we currently have any significant direct foreign exchange risk and have not used any derivative financial instruments to hedge exposure to such risk. Also, considering the volume of its business, the impact of foreign exchange risk is limited.
c. Interest rate risk
The interest rate risk is the risk that future cash flows will fluctuate as a result of changes in market interest rates. Our exposure to interest rate risk primarily relates to the interest rates from our lessors, convertible debenture and our private lenders. We have not been exposed to material risks due to the fact that our leasing obligations’ interest rate and the private loan’s interest are fixed at commence date of the leases and loans and we have not used any derivative financial instruments to manage our interest risk exposure. However, we cannot provide assurance that we will not be exposed to material risks due to changes in market interest rate in the future.
F-17
QUANOME TECHNOLOGIES, INC. (FORMERLY KNOWN AS LAKESIDE HOLDING LIMITED)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)
Concentrations and risks (cont.)
d. Liquidity risk
Liquidity risk arises through the excess of financial obligations over available financial assets due at any point in time. Our objective in managing liquidity risk is to maintain sufficient readily available reserves in order to meet our liquidity requirements at any point in time. The Company monitors and analyzes its cash flow position, its ability to generate sufficient revenue sources in the future and its operating and capital expenditure commitments. The Company typically funds the working capital needed primarily from operations, loans, shareholder advances to the Company, as well as the external financing activities.
e. Significant customers and suppliers
For the three months ended September 30, 2026, four third-party customers individually accounted for
As of September 30, 2026, four third-party customers individually accounted for
For the three months ended September 30, 2026, two third-party suppliers individually accounted for
As of September 30, 2026, three third-party suppliers individually accounted for
Recent accounting pronouncements
The Company considers the applicability and impact of all accounting standards updates issued by the Financial Accounting Standards Board (“FASB”). Accounting standards that have been issued but are not listed below were assessed and determined either to be not applicable or not expected to have a material impact on the Company’s unaudited condensed consolidated financial statements or related disclosures.
Recently Adopted Accounting Standards
In November 2024, the FASB issued ASU 2024-04, “Debt - Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments,” which clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion. The amendments also clarify some specific applications of induced conversion guidance and that the guidance applies to a convertible debt instrument that is not currently convertible as long as it had a substantive conversion feature as of both its issuance date and the date the inducement offer is accepted. The new guidance is required to be applied either prospectively or retrospectively. The guidance may be applied prospectively or retrospectively. The Company adopted this guidance effective July 1, 2026. The adoption did not have a material impact on the Company’s unaudited condensed consolidated financial statements and related disclosures.
F-18
QUANOME TECHNOLOGIES, INC. (FORMERLY KNOWN AS LAKESIDE HOLDING LIMITED)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)
Recent accounting pronouncements (cont.)
Recently Adopted Accounting Standards (cont.)
In July 2025, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2025-05, “Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets”. ASU 2025-05 provides a practical expedient that allows entities to assume that current conditions as of the balance sheet date do not change for the remaining life of the asset when estimating expected credit losses for current accounts receivable and current contract assets. The amendments of ASU 2025-05 should be applied prospectively and are effective for annual and interim periods beginning after December 15, 2025, with early adoption permitted. The guidance became effective for the Company on July 1, 2026. The Company evaluated the amendments and determined that they did not have a material impact on its unaudited condensed consolidated financial statements and related disclosures.
Accounting standards issued but not yet adopted
In November 2024, the FASB issued ASU 2024-03, “Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses” and issued subsequent amendment within ASU 2025-01. The amendments require disaggregation disclosure for certain expense captions presented on the face of income statement, as well as additional disclosure about selling expenses. This guidance is effective for the Company for the year ending June 30, 2028 and interim reporting periods during the year ending December 31, 2029. Early adoption is permitted. The Company is evaluating the impact of the adoption of this guidance on its disclosures.
In May 2025, the FASB issued ASU 2025-03, “Business Combinations (Topic 805) and Consolidation (Topic 810): Determining the Accounting Acquirer in the Acquisition of a Variable Interest Entity,” which requires an entity involved in an acquisition transaction effected primarily by exchanging equity interests when the legal acquiree is a VIE that meets the definition of a business to consider specific factors to determine the accounting acquirer and removes the requirement that the primary beneficiary always is the acquirer for certain transactions. Under the amendments, acquisition transactions in which the legal acquiree is a VIE will, in more instances, result in the same accounting outcomes as economically similar transactions in which the legal acquiree is a voting interest entity. The amendments do not change the accounting for a transaction determined to be a reverse acquisition or a transaction in which the legal acquirer is not a business and is determined to be the accounting acquiree. The new guidance is required to be applied prospectively to any acquisition transaction that occurs after the initial application date. This guidance is effective for the Company for the year ending June 30, 2028. Early adoption is permitted. The Company is evaluating the impact of the adoption of this guidance.
In September 2025, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2025-07, Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606): Scope Refinements. This update clarifies the application of derivative accounting to certain contracts and refines the guidance for share-based noncash consideration received from customers. Specifically, ASU 2025-07 introduces a scope exception for contracts that are not exchange-traded and whose underlying is tied to operations or activities specific to one party. It also clarifies that share-based noncash consideration from a customer should initially be accounted for under Topic 606 until the right to receive or retain such consideration becomes unconditional, at which point financial instruments guidance may apply. The amendments are effective for the Company for the year ending June 30, 2028, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2025-07 on its unaudited condensed consolidated financial statements and related disclosures.
The Company does not believe other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the Company’s unaudited condensed consolidated balance sheets, statements of operations and comprehensive loss and statements of cash flows.
F-19
QUANOME TECHNOLOGIES, INC. (FORMERLY KNOWN AS LAKESIDE HOLDING LIMITED)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 3 — ACCOUNTS RECEIVABLE, NET
Accounts receivable, net consists of the following:
| September 30, 2026 | June 30, 2026 | |||||||
| Accounts receivable | $ | $ | ||||||
| Less: allowance for credit loss | ( | ) | ( | ) | ||||
| Accounts receivable, net | $ | $ | ||||||
The movement of allowance for credit loss for the three months ended September 30, 2026 and the year ended June 30, 2026 is as follows:
| September 30, 2026 | June 30, 2026 | |||||||
| Beginning balance | $ | $ | ||||||
| (Reversal) provision of expected credit loss allowance | ( | ) | ||||||
| Effect of foreign exchange translation | ||||||||
| Ending balance | $ | $ | ||||||
The Company recorded a reversal of allowance for credit loss of $
NOTE 4 — INVENTORIES, NET
Inventories, net consists of the following:
| As of September 30, 2026 | As of June 30, 2026 | |||||||
| Finished goods | $ | $ | ||||||
| Less: inventory allowance | — | — | ||||||
| Inventories, net | $ | $ | ||||||
F-20
QUANOME TECHNOLOGIES, INC. (FORMERLY KNOWN AS LAKESIDE HOLDING LIMITED)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 5 — LOAN RECEIVABLE FROM THIRD PARTIES, NET
Loan receivable from third parties, net consists of the following:
| As of September 30, 2026 | As of June 30, 2026 | |||||||
| Unrelated individual A (1) | $ | $ | ||||||
| Unrelated individual B (2) | ||||||||
| Unrelated individual C | ||||||||
| Gross loan receivable | ||||||||
| Less: allowance for credit loss | ( | ) | ( | ) | ||||
| Loan receivable, net | $ | $ | ||||||
| (1) | |
| (2) | During the year ended June 30, 2026, the Company entered into a loan agreement with a third party with a principal of $ |
The Company recognized interest income of $
For the three months ended September 30, 2026, the Company recognized an allowance for expected credit loss allowance of $
F-21
QUANOME TECHNOLOGIES, INC. (FORMERLY KNOWN AS LAKESIDE HOLDING LIMITED)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 6 — PREPAYMENT, DEPOSIT AND OTHER RECEIVABLE, NET
| As of September 30, 2026 | As of June 30, 2026 | |||||||
| Prepayment, other receivable and deposit (1) | $ | $ | ||||||
| Prepayment for purchase of furniture and equipment (2) | - | |||||||
| Rent deposits | ||||||||
| Advance to suppliers | ||||||||
| Ending balance | ||||||||
| Less: non-current portion (2) | ( | ) | ( | ) | ||||
| Current portion | $ | $ | ||||||
| (1) |
The prepaid consulting expenses are recognized in general and administrative expenses over the respective service periods as the consulting services are rendered.
For the three months ended September 30, 2026 and 2025, the Company recognized share-based compensation expenses of $ |
| (2) |
NOTE 7 — PROPERTY AND EQUIPMENT, NET
Property and equipment, net consists of the following:
| September 30, 2026 | June 30, 2026 | |||||||
| Furniture and Fixtures | $ | $ | ||||||
| Machinery equipment | ||||||||
| Vehicles | ||||||||
| Software | ||||||||
| Leasehold improvement | ||||||||
| Subtotal | ||||||||
| Less: accumulated depreciation | ( | ) | ( | ) | ||||
| Property and equipment, net | $ | $ | ||||||
Depreciation expense was $
F-22
QUANOME TECHNOLOGIES, INC. (FORMERLY KNOWN AS LAKESIDE HOLDING LIMITED)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 8 — INTANGIBLE ASSETS, NET
Net intangible assets consist of the following:
| September 30, 2026 | June 30, 2026 | |||||||
| License | $ | $ | ||||||
| Less: accumulated amortization | ( | ) | ( | ) | ||||
| Intangible asset, net | $ | $ | ||||||
On November 5, 2024, the Company purchased a license of pharmaceutical distribution in Mainland China through its acquisition of
For the three months ended September 30, 2026 and 2025, the Company recorded amortization expense of $
NOTE 9 — LEASES
The Company has two lease agreements for office and dormitory. During the three months ended September 30, 2026, the Company entered into a modification of its existing operating lease agreement, resulting in a reduction in monthly rental payments. The modification resulted in a noncash decrease of $
Total operating lease expenses on offices for the three months ended September 30, 2026 and 2025 were $
The following table includes supplemental cash flow and non-cash information related to leases:
| For the Three Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| Cash paid of amounts included in the measurement of lease liabilities: | ||||||||
| Operating cash flows from operating leases | $ | $ | ||||||
The weighted average remaining lease terms and discount rates for all of operating lease is as follows:
| September 30, 2026 | June 30, 2026 | |||||||
| Weighted-average remaining lease term (years): | ||||||||
| Operating lease | ||||||||
| Weighted average discount rate: | ||||||||
| Operating lease | % | % | ||||||
F-23
QUANOME TECHNOLOGIES, INC. (FORMERLY KNOWN AS LAKESIDE HOLDING LIMITED)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 9 — LEASES (cont.)
The following is a schedule of maturities of operating lease liabilities as of September 30, 2026:
Operating leases
| Twelve months ending September 30, | Repayment | |||
| 2027 | $ | |||
| 2028 | ||||
| 2029 | ||||
| 2030 | ||||
| Total future minimum lease payments | ||||
| Less: imputed interest | ( | ) | ||
| Total operating lease liabilities | $ | |||
NOTE 10 — ACCRUED LIABILITIES AND OTHER PAYABLES
Accrued liabilities and other payables comprise the following amounts relating to the operation of the Company
| As of September 30, 2026 | As of June 30, 2026 | |||||||
| Credit card payables | $ | $ | ||||||
| Payroll liabilities | ||||||||
| Accrued expense | ||||||||
| Interest payable to a related party | - | |||||||
| Other payables | ||||||||
| Total | $ | $ | ||||||
NOTE 11 — LOANS PAYABLE
The loan balance consists of the following:
| As of September 30, 2026 | As of June 30, 2026 | |||||||
| Loan A | $ | - | $ | |||||
| Loan B | - | |||||||
| Loan C | ||||||||
| Total | ||||||||
| Less: loan payable, current | ( | ) | ( | ) | ||||
| Loan payable, non-current | $ | $ | ||||||
F-24
QUANOME TECHNOLOGIES, INC. (FORMERLY KNOWN AS LAKESIDE HOLDING LIMITED)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 11 — LOANS PAYABLE (cont.)
| (A) | |
| (B) | |
| (C) |
NOTE 12 — CONVERTIBLE DEBTS
On March 5, 2025, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with an institutional investor (the “Investor”).
Under the Securities Purchase Agreement, the Company agreed to issue
Pursuant to the Securities Purchase Agreement, the Company agreed to issue, upon the consummation of the closing of each tranche, common stock purchase warrants (“Warrants”) to the Investor, in each case to purchase a number of shares of common stock determined by dividing
F-25
QUANOME TECHNOLOGIES, INC. (FORMERLY KNOWN AS LAKESIDE HOLDING LIMITED)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 12 — CONVERTIBLE DEBTS (cont.)
The Note does not bear any interest absent an Event of Default (as defined in the Note) and matures on June 5, 2026. Commencing on the earlier of (i) the 60-day anniversary after the date hereof and (ii) the date on which the first Resale Registration Statement shall have been declared effective by the Commission, the Company is required to pay to the Investor the outstanding principal balance under the Note in monthly installments, on such date and each one (1) month anniversary thereof, in an amount equal to
On April 22, 2025, the Second Closing of the First Tranche was consummated. The Company issued Investor Warrants to purchase
The Company evaluated the Note with conversion features and the detachable warrant under the guidance of ASC 470-20, “Debt with Conversion and Other Options, as amended by ASU 2020-06” and ASC 815, “Derivatives and Hedging.” The Company determined that the warrant met the criteria for equity classification under ASC 815-40. Accordingly, the relative fair value of the warrant was recorded as a component of additional paid-in capital on the issuance date.
The Company determined that embedded derivative meets the definition of derivative instruments under ASC 815, Derivatives and Hedging. Following the adoption of ASU 2020-06, the Notes are recorded as a single unit within liabilities in the unaudited condensed consolidated balance sheets as the conversion features within the Notes are not derivatives that require bifurcation and the Notes do not involve a substantial premium.
The Company accounted for the host debt as a liability recorded at amortized cost under ASC 470-10, net of issuance costs and any discount that allocated to debt component.
The debt discount and issuance cost will be amortized to interest expense over the term of the Note using the effective interest method.
The Company recorded $
The Company recorded $
F-26
QUANOME TECHNOLOGIES, INC. (FORMERLY KNOWN AS LAKESIDE HOLDING LIMITED)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 12 — CONVERTIBLE DEBTS (cont.)
The relative fair value of warrants of first closing of the first tranche was estimated using the Black-Scholes pricing model with the following weighted-average assumptions: market value of underlying share of $
The relative fair value of warrants of second closing of the first tranche was estimated using the Black-Scholes pricing model with the following weighted-average assumptions: market value of underlying share of $
The Company applied the relative fair value method to allocate the proceeds from the issuance of convertible debt. The Note’s original issue discount and incurred total issuance costs were allocated to the note payable and warrants on the relative fair value basis in accordance with ASC 835-30 and ASC 470-20. The debt discount and issuance cost allocated to the loan component will be amortized to interest expense over the term of the Convertible Debts using the effective interest method.
The initial purchaser’s discount and debt issuance costs primarily consisted of underwriting fees, lawyers fee, investor legal fee, auditor fee and SEC registration fee.
| Amount | Equity Component | Debt Component | ||||||||||
| Initial purchaser’s debt discount | $ | $ | $ | |||||||||
| Debt issuance cost | ||||||||||||
| Total | $ | $ | $ | |||||||||
The portion allocated to debt component is amortized to interest expense using the effective interest method over the effected life of the Notes, or approximately
During the three months ended September 30, 2025, the holder of the Company’s convertible notes converted portions of the outstanding principal balance into shares of the Company’s common stock pursuant to the original terms of the respective note agreements. No common shares were issued upon conversion of convertible notes during the three months ended September 30, 2026.
The conversions were accounted for in accordance with ASC 470-20, Debt with Conversion and Other Options, as conversions under the original terms of the agreements. Accordingly, the carrying amount of the debt, including any unamortized discount, was reclassified to equity upon conversion, and no gain or loss was recognized.
During the three months ended September 30, 2026, the Company repaid in full the outstanding principal balance, together with accrued interest. The Company had no outstanding convertible debt obligations as of September 30, 2026.
F-27
QUANOME TECHNOLOGIES, INC. (FORMERLY KNOWN AS LAKESIDE HOLDING LIMITED)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 12 — CONVERTIBLE DEBTS (cont.)
As of September 30, 2026, the Company had no convertible notes outstanding.
| June 30, 2026 | ||||
| Long term debt | ||||
| Outstanding principal | $ | |||
| Unamortized Initial Purchaser’s debt discount and debt issuance cost | - | |||
| Accrued interest | ||||
| Net carrying amount | $ | |||
| Convertible debts, current | $ | |||
The Company recognized interest expense of $nil and $
NOTE 13 — GENERAL AND ADMINISTRATIVE EXPENSES
| For the Three Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| Payroll and staff benefit expense | $ | $ | ||||||
| Professional expense | ||||||||
| Travelling and entertainment | - | |||||||
| Office expense | ||||||||
| Lease expense | ||||||||
| Insurance | ||||||||
| Other expense | ||||||||
| Depreciation on plant property and equipment | ||||||||
| Advertising | - | |||||||
| Rent expense of short-term lease | ||||||||
| Amortization on intangible assets | ||||||||
| Bank charge | ||||||||
| Motor expense | ||||||||
| Management fee | - | |||||||
| Repair & maintenance | ||||||||
| Total | $ | $ | ||||||
F-28
QUANOME TECHNOLOGIES, INC. (FORMERLY KNOWN AS LAKESIDE HOLDING LIMITED)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 14 — SELLING EXPENSES
| For the Three Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| Payroll | $ | $ | ||||||
| Market research expense | ||||||||
| Warehousing and logistics expenses | ||||||||
| Entertainment expense | ||||||||
| Business development expense | ||||||||
| Others | ||||||||
| Total | $ | $ | ||||||
NOTE 15 — INCOME TAXES
Corporate Income Taxes
Under current U.S. federal tax law, corporations are subject to a federal corporate income tax rate of
Under the PRC Enterprise Income Tax Law (the “EIT Law”), the standard enterprise income tax rate for domestic enterprises and foreign invested enterprises is
Under the current tax laws of Cayman Islands, the Company’s subsidiaries in Cayman Islands are not subject to tax on income or capital gain. Additionally, the Cayman Islands does not impose a withholding tax on payments of dividends to shareholders.
As of September 30, 2026 and June 30, 2026, the Company did not have an accrued liability for uncertain tax positions and does not anticipate recognition of any significant liabilities for uncertain tax positions during the next 12 months. For the three months ended September 30, 2026 and 2025, no amounts were incurred for income tax uncertainties or interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals, or material deviation from its position. The Company’s tax years since its formation remain subject to possible income tax examination by its major taxing authorities for all periods.
The Income tax expense applicable to loss before income taxes consists of the following:
| For the Three Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| Current income tax expense: | ||||||||
| Federal | $ | - | $ | - | ||||
| State | - | - | ||||||
| Foreign | ||||||||
| Total current income tax | ||||||||
| Deferred income tax benefit | ||||||||
| Federal | - | - | ||||||
| State | - | - | ||||||
| Foreign | - | ( | ) | |||||
| Total deferred income tax benefit | - | ( | ) | |||||
| Income tax expense | $ | $ | ||||||
F-29
QUANOME TECHNOLOGIES, INC. (FORMERLY KNOWN AS LAKESIDE HOLDING LIMITED)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 15 — INCOME TAXES (cont.)
Corporate Income Taxes (cont.)
(Loss) income before income tax consists of the following:
| For the Three Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| U.S. | ( | ) | ( | ) | ||||
| Foreign | ||||||||
| Loss before income tax | $ | ( | ) | $ | ( | ) | ||
The income tax expense differs from the amount computed by applying the U.S. federal statutory rate of
| For the Three Months Ended September 30, | ||||||||
| 2026 | ||||||||
| US Federal Statutory Tax Rate | $ | ( | ) | % | ||||
| State and Local Income Taxes, Net of Federal Income Tax Effect (1) | ( | ) | - | % | ||||
| Change in valuation allowance | ( | )% | ||||||
| Foreign tax effects | ||||||||
| PRC | ||||||||
| Increased statutory tax rate on quality income | ( | )% | ||||||
| Non-deductible expense | ( | )% | ||||||
| Change in valuation allowance | ( | ) | % | |||||
| Other adjustment | ( | ) | % | |||||
| Total income tax expense | $ | ( | )% | |||||
| (1) |
The income tax expense differs from the amount computed by applying the U.S. federal statutory rate of
| For the Three Months Ended September 30, | ||||
| 2025 | ||||
| Loss before tax | $ | ( | ) | |
| Statutory state tax rate | % | |||
| Income tax recovery at the federal statutory rate | ( | ) | ||
| Effect of preferential tax benefit on assessable profits of subsidiaries incorporated in the PRC | ||||
| Non-deductible expense | ||||
| Change in valuation allowance | ||||
| Total income tax expense | $ | |||
F-30
QUANOME TECHNOLOGIES, INC. (FORMERLY KNOWN AS LAKESIDE HOLDING LIMITED)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 15 — INCOME TAXES (cont.)
Corporate Income Taxes (cont.)
The amount of cash paid for income taxes (net of refunds) for the three months ended September 30, 2026 is as follows:
| For the Three Months Ended September 30, | ||||
| 2026 | ||||
| Federal | $ | - | ||
| State | - | |||
| Foreign | ||||
| PRC | ||||
| Total income taxes paid, net of refunds | $ | |||
The Company’s deferred tax assets and liabilities consist of the following:
| As of September 30, 2026 | As of June 30, 2026 | |||||||
| Deferred tax assets: | ||||||||
| Allowance for credit loss – account receivable | $ | $ | ||||||
| Allowance for credit loss – loan receivable | ||||||||
| Allowance for credit loss – advances to supplier | ||||||||
| Accrued advertising expense | - | |||||||
| Refundable liability net of right of return asset | ||||||||
| Non-capital loss carried forward | ||||||||
| Total deferred tax assets | ||||||||
| Less: Valuation allowance | ( | ) | ( | ) | ||||
| Total deferred tax assets, net of valuation allowance | ||||||||
| Net off against deferred tax liabilities | ( | ) | ( | ) | ||||
| Deferred tax assets, net | $ | - | $ | - | ||||
| Deferred tax liabilities: | ||||||||
| Intangible asset – license | $ | ( | ) | $ | ( | ) | ||
| Total deferred tax liabilities | ( | ) | ( | ) | ||||
| Net off against deferred tax assets | ||||||||
| Deferred tax liabilities, net | $ | - | $ | - | ||||
As of September 30, 2026 and June 30, 2026, the accumulated tax losses of subsidiary incorporated in the U.S. of approximately $
The deferred tax liability related to the license is expected to reverse through future amortization over the period ending October 22, 2029, and the resulting taxable income is expected to be offset by the Company’s tax loss carryforwards, accordingly, this deferred tax liability has been offset against the Company’s deferred tax assets
Uncertain tax positions
The Company evaluates each uncertain tax position (including the potential application of interest and penalties) based on the technical merits, and measures the unrecognized benefits associated with the tax positions. As of September 30, 2026 and 2025, the Company did not have any significant unrecognized uncertain tax positions. The Company did not incur interests and penalties tax for the three months ended September 30, 2026 and 2025.
F-31
QUANOME TECHNOLOGIES, INC. (FORMERLY KNOWN AS LAKESIDE HOLDING LIMITED)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 15 — INCOME TAXES (cont.)
Corporate Income Taxes (cont.)
PRC
According to PRC Tax Administration and Collection Law, the statute of limitations is three years if the underpayment of taxes is due to computational errors made by the taxpayer or withholding agent. The statute of limitations will be extended to five years under special circumstances, which are not clearly defined (but an underpayment of tax liability exceeding RMB
U.S.
The statute of limitations for the Company’s subsidiary in the U.S. is
NOTE 16 — RELATED PARTY TRANSACTION AND BALANCE
The relationship of related parties is summarized as follows:
| Name of Related Party | Relationship with the Company | |
| Mr. Yang Li (“Mr. Li”) |
| a) | The Company had the following balances with related parties: |
| As of | ||||||||
| September 30, 2026 | June 30, 2026 | |||||||
| Amount due to a related party | ||||||||
| Mr. Li (1) | $ | $ | ||||||
| Loan payable to a related party | ||||||||
| Mr. Li (2) | $ | - | ||||||
| Interest payable to a related party | ||||||||
| Mr. Li (2) | $ | - | ||||||
| (1) | |
| (2) | On September 28, 2026, the Company entered into a revolving loan agreement with Yang Li, the Company’s Chief Executive Officer and Chairman of the Board of Directors, pursuant to which the Company may borrow up to an aggregate outstanding principal amount of $
The loans bear interest at a rate of
The revolving loan is unsecured and is not collateralized by any specific assets of the Company or supported by any personal or corporate guarantees. However, pursuant to the loan agreement, the Company is subject to certain restrictive covenants, including restrictions on the disposal of assets, creation of liens over its assets, assignment of income and incurrence of additional indebtedness without the Lender’s prior written consent, subject to certain permitted exceptions.
As of September 30, 2026, the outstanding loan balance under the agreement was $ |
F-32
QUANOME TECHNOLOGIES, INC. (FORMERLY KNOWN AS LAKESIDE HOLDING LIMITED)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 17 — DISCONTINUED OPERATIONS AND SALES OF ABL CHICAGO
During the third quarter of 2026, the Company entered into the Share Purchase Agreement (“SPA”) to sell the equity interests of its subsidiaries that own and operate its ABL business (the “Sale Transaction”), subject to shareholder and regulatory approvals, for a total base purchase price of $
On February 12, 2026, the sale of
Results of Discontinued Operations
Net loss from discontinued operations details is as follows:
| For the Three Months Ended September 30, 2025 | ||||
| Revenue | $ | |||
| Cost of revenue | ||||
| Operating expenses | ||||
| Loss from operation | ( | ) | ||
| Other expense | ( | ) | ||
| Net loss from discontinued operations, before tax | ( | ) | ||
| Income tax expense | - | |||
| Net loss from discontinued operations, net of tax provision | $ | ( | ) | |
Revenue from discontinued operation
ABL Chicago generates revenue from providing cross-border ocean and airfreight solutions. No practical expedients were used when adoption ASC606. Revenue recognition policies are as follows:
Revenue from cross-border freights solutions
The Company provides comprehensive services in the United States for customers to transport goods from overseas to the United States and from the United States to overseas. Operating under service contracts, for goods entering the United States, after the goods arrive at a U.S. seaports or airports, the Company offers customs clearance, container unloading, storage, unpacking, packing, and transportation services to the locations specified by the customers. For customers shipping goods overseas, the Company provides cargo space arrangements, storage, packing, export customs clearance, and arranges transportation to seaports or airports for loading.
The transaction price is determined based on the range of services provided and the volume of goods. The Company considers these comprehensive services as one performance obligation since these promises are not distinct within the context of the contract, and the bundle of integrated services represents a combined output. This performance obligation is satisfied over time as customers receive the benefits of these services during the process of transporting goods from one location to another.
F-33
QUANOME TECHNOLOGIES, INC. (FORMERLY KNOWN AS LAKESIDE HOLDING LIMITED)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 17 — DISCONTINUED OPERATIONS AND SALES OF ABL CHICAGO (cont.)
Revenue from cross-border freights solutions (cont.)
For goods entering the United States, the Company determines that the performance period for revenue recognition is between the pickup date and the date of completing delivery. For customers shipping goods overseas with cargo space booking service, the Company determines that the performance period for revenue recognition is between the container or cargo space confirmed date and the date of arrival at destination. For customers shipping goods overseas without cargo space booking service, the Company determines that the performance period for revenue recognition is between pickup date and the date when the goods depart from airport or port. The performance period may be estimated if the date of completing delivery or the departure date or arrival date has not occurred by the reporting date. The Company has determined that revenue recognition over the time in transit provides a reasonable estimate of the transfer of services to its customers as it depicts the pattern of the Company’s performance under the contracts with its customers. Determining the performance period and the progress of the transportation as of the reporting date requires management’s estimation and judgement, which may impact the timing of revenue recognition.
For customers with goods entering the United States, we offer customs clearance, container unloading, storage, unpacking, packing, and transportation services to customer-specified locations after the goods arrive at a U.S. seaport or airport. For customers shipping goods overseas, we provide cargo space arrangement, storage, packing, export customs clearance, and transportation to the seaport or airport for loading. The performance obligation is satisfied over time as customers receive the benefits of these services during the process of transporting goods from one location to another. As a result, we recognize revenue over time. We believe that the methodology employed is comparable to that of other global logistics companies and offers faithful depiction of the services rendered to customers.
Principal and agent considerations
In the Company’s transportation business, the Company utilizes independent contractors and third-party carriers and related party carriers in the performances of some transportation services as and when needed. U.S. GAAP requires us to evaluate, using a control model, whether the Company itself promises to provide services to the customers (as a principal) or to arrange for services to be provided by another party (as an agent). Based on the Company’s evaluation using a control model, the Company determined that in all of its major business activities, it serves as a principal rather than an agent within their revenue arrangements. Revenue and the associated purchased transportation costs are both reported on a gross basis within the unaudited condensed consolidated statements of income (loss) and comprehensive income (loss).
Related party transactions
a) Summary of related parties’ transactions
| For the three months Ended September 30, 2025 | ||||
| Revenue from ABL Wuhan (a) | $ | |||
| Revenue from ABL Shenzhen (a) | $ | |||
| Revenue from ABL LAX (a) | $ | |||
| Rental income from Weship (b) | $ | |||
| Rental income from Intermodal (c) | $ | |||
| Cost of revenue charged by Weship (d) | $ | |||
| Cost of revenue charged by Intermodal (e) | $ | |||
| Cost of revenue charged by ABL Wuhan (f) | $ | |||
| Interest expenses charged by ABL Shenzhen (g) | $ | |||
F-34
QUANOME TECHNOLOGIES, INC. (FORMERLY KNOWN AS LAKESIDE HOLDING LIMITED)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 17 — DISCONTINUED OPERATIONS AND SALES OF ABL CHICAGO (cont.)
Related party transactions (cont.)
a) Summary of related parties’ transactions (cont.)
During the three months ended September 30, 2025, the Company had the following transactions with its related parties — Weship, ABL Wuhan, ABL Shenzhen, ABL LAX and Intermodal
| (a) |
| (b) | ||
| (c) |
| (d) |
| (e) |
| (f) | ||
| (g) |
b) Salaries and employee benefits paid to major shareholders
| For the three months Ended September 30, 2025 | ||||
| Mr. Henry Liu | $ | |||
| Mr. Shuai Li | ||||
| Total | $ | |||
F-35
QUANOME TECHNOLOGIES, INC. (FORMERLY KNOWN AS LAKESIDE HOLDING LIMITED)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 18 — SHAREHOLDERS’ EQUITY
Common Stock
The Company was incorporated under the laws of the State of Nevada on August 28, 2023. In accordance with the Company’s Articles of Incorporation, the Company is authorized to issue
On October 25, 2023, the Company amended its Articles of Incorporation to increase its number of authorized common stock from
On March 29, 2024, a
On July 1, 2024, the Company closed its IPO of
On July 2, 2026, the Company filed a Certificate of Amendment to its articles of incorporation, as amended (“Amended Articles of Incorporation”), with the Secretary of State of the State of Nevada (the “Nevada Secretary of State”) to (i) increase the number of authorized shares of common stock, par value $
Private offering
On June 24, 2025, the Company entered into a Securities Purchase Agreement with certain investors for the issuance and sale of an aggregate of
On July 16, 2025, the Company entered into Securities Purchase Agreements with certain investors for the issuance and sale of an aggregate of
On August 4, 2025, the Company entered into Securities Purchase Agreements with certain investors for the issuance and sale of an aggregate of
On December 15, 2025, the Company entered into Securities Purchase Agreements with certain investors for the issuance and sale of an aggregate of
F-36
QUANOME TECHNOLOGIES, INC. (FORMERLY KNOWN AS LAKESIDE HOLDING LIMITED)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 18 — SHAREHOLDERS’ EQUITY (cont.)
Common Stock (cont.)
Private offering (cont.)
On December 29, 2025, the Company entered into Securities Purchase Agreements with certain investors for the issuance and sale of an aggregate of
Convertible debts conversion
During the three months ended September 30, 2025, holders of the Company’s convertible notes elected to convert an aggregate principal amount of $
Common Shares Issued for Service
On July 4, 2025, the Company signed a consulting agreement (the “Consulting Agreement”) with FirsTrust China Ltd. (“FirsTrust”) to provide professional consulting and advisory services to the Company for twelve months from July 7, 2025 in exchange for
On July 4, 2025, the Company entered into a consulting agreement (the “Consulting Agreement”) with SNC Investment Group Limited (“SNC”), under which SNC will provide strategic planning and corporate communication services to the Company for a twelve-month period beginning August 7, 2025. As compensation for these services, the Company agreed to issue
On July 21, 2025, the Company entered into a consulting agreement (the “Consulting Agreement”) with China PINX International Investment Group Limited (“China PINX”) to provide merger and acquisition consulting and other related service to the Company for a period from July 21, 2025 to June 30, 2026. Upon signing the agreement, the Company issued
On August 1, 2025, the Company entered into a consulting agreement (the “Consulting Agreement”) with Jolly Good River Group Limited (“Jolly”) to provide strategic consulting services to the Company for a twelve-month period beginning August 1, 2025. As compensation for these services, the Company agreed to issue
On December 13, 2025, the Company entered into a consulting agreement (the “Consulting Agreement”) with Nan Zhang to provide management consulting and advisory services to the Company for a twelve-month period beginning December 13, 2025. As compensation for these services, the Company agreed to issue
F-37
QUANOME TECHNOLOGIES, INC. (FORMERLY KNOWN AS LAKESIDE HOLDING LIMITED)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 18 — SHAREHOLDERS’ EQUITY (cont.)
Common Stock (cont.)
Common Shares Issued for Service (cont.)
On December 15, 2025, the Company entered into a consulting agreement (the “Consulting Agreement”) with Zhixin Li to provide business expansion, merger and acquisition consulting services to the Company for a twelve-month period beginning December 15, 2025. As compensation for these services, the Company agreed to issue
On December 23, 2025, the Company entered into a consulting agreement (the “Consulting Agreement”) with Shengrong Venture Limited (“Shengrong”) to provide general operating advisory services to the Company for a twelve-month period beginning December 23, 2025. As compensation for these services, the Company agreed to issue
On December 23, 2025, the Company entered into a consulting agreement (the “Consulting Agreement”) with SNC Investment Group Limited (“SNC”) to provide capital markets advisory services and guidance to the Company for a twelve-month period beginning December 23, 2025. As compensation for these services, the Company agreed to issue
For the three months ended September 30, 2026, no common shares were issued under consulting agreements. The Company recognized stock-based compensation expense for consulting services of $
As of September 30, 2026 and June 30, 2026,
Representative’s Warrants
Pursuant to the Underwriting Agreement, the Company issued to the Representative and its designee warrants (the “Representative’s Warrants”) to purchase
Management determined that these warrants meet the requirements for equity classification under ASC 815-40 because they are indexed to their own shares and meet the requirements for equity classification. The warrants were recorded at their fair value on the date of grant as a component of shareholders’ equity. The fair value of these warrants was $
As of September 30, 2026,
F-38
QUANOME TECHNOLOGIES, INC. (FORMERLY KNOWN AS LAKESIDE HOLDING LIMITED)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 18 — SHAREHOLDERS’ EQUITY (cont.)
Common stock purchase warrants
Pursuant to the Securities Purchase Agreement, the Company agreed to issue, upon the consummation of the closing of each tranche, common stock purchase warrants (“Warrants”) to the Investor (see Note 12).
As of September 30, 2026,
As of September 30, 2026,
Subscription receivable
As of September 30, 2026, a total of $
This amount is recorded as Subscription Receivable and is presented as a deduction from Shareholders’ Equity in the accompanying Condensed Consolidated Balance Sheets. The Company expects to collect the full outstanding balance during the next quarter.
Statutory reserves
The Company is required to make appropriations to certain reserve funds, comprising the statutory surplus reserve and the discretionary surplus reserve, based on after-tax net income determined in accordance with generally accepted accounting principles of the PRC (“PRC GAAP”). Appropriations to the statutory surplus reserve are required to be at least
NOTE 19 — LOSS PER SHARE
For the three months ended September 30, 2026 and 2025, all potentially dilutive securities, including the convertible debenture and warrants, were excluded from the calculation of diluted loss per share because the Company was in a loss position.
| For the Three Months Ended September 30 | ||||||||
| 2026 | 2025 | |||||||
| Net loss from continuing operations | $ | ( | ) | $ | ( | ) | ||
| Net loss from discontinued operation | - | ( | ) | |||||
| Net loss attributable to the Company | $ | ( | ) | $ | ( | ) | ||
| Weighted average number of common shares outstanding – Basic and Diluted | ||||||||
| Basic and Diluted Net Loss per Common Share | ||||||||
| Continuing operations | $ | ( | ) | $ | ( | ) | ||
| Discontinued operations, net of tax | $ | - | $ | ( | ) | |||
| Total basic and diluted net loss per common share attributable to the Company | $ | ( | ) | $ | ( | ) | ||
F-39
QUANOME TECHNOLOGIES, INC. (FORMERLY KNOWN AS LAKESIDE HOLDING LIMITED)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 20 — SEGMENT INFORMATION
The Company follows Financial Accounting Standards Board (FASB”) Accounting Standards codification “ASC”) Topic 280, Segment Reporting, as amended by Accounting Standards Update (“ASU”) No.2023-07. Segment Reporting Topic 280: Improvements to Reportable Segment Disclosures, the Company continually monitors the reportable segments for changes in fact and circumstances to determine whether changes in the identification or aggregation of operating segments are necessary. An operating segment is a component of the Company that engages in business activities from which it may earn revenues and incur expenses, and is identified on the basis of the internal financial reports that are provided to and regularly reviewed by the Company’s chief operating decision maker in order to allocate resources and assess performance of the segment. The Company adopted ASU 2023-07 on July 1, 2024 and applied the amendments retrospectively to all prior periods presented. The adoption affected the Company’s segment disclosures but did not affect the recognition or measurement of amounts in its unaudited condensed consolidated financial statements.
The Company’s CODM is Mr. Yang Li, the CEO. The Company has determined that it has only one operating segment and therefore one reportable segment after considering several sources of information, including the Company’s internal organizational structure, the basis on which budgets and forecasts are prepared, the financial information that the Company’s CODM reviews in evaluating company performance and determining how resources should be allocated, and how the Company releases information to the public and analysts. The CODM manages all business activities on a unaudited condensed consolidated basis, and as a result, the Company has concluded that as of September 30, 2026, there is only one operating segment and therefore one reportable segment.
The Company’s one reportable segment serves its customers primarily by providing pharmaceutical products in China. The Company generates a substantial percentage of its revenue from selling pharmaceutical products on a direct basis, whereby it is exposed to the risks and rewards of ownership of the material while in its possession.
As the one reportable segment is managed on a consolidated basis, the measure of segment profit or loss is unaudited condensed consolidated net loss.
The Company regularly provides the CODM with a reporting package that is structured similarly to the statements of earnings, and the CODM reviews unaudited condensed consolidated net loss as a key performance measure of loss for the Company’s single reportable segment and reviews significant expenses on a unaudited condensed consolidated basis consistent with the presentation on the unaudited condensed consolidated statements of operations and comprehensive loss. The CODM’s review is focused on the unaudited condensed consolidated results for the Company.
The following table presents the significant expenses that are regularly provided to the CODM for the one reportable segment and the required disclosable amounts that are included in unaudited condensed consolidated and combined net loss for the three months ended September 30, 2026 and 2025.
| For the Three Months Ended September 30 | ||||||||
| 2026 | 2025 | |||||||
| Revenue from external customers | $ | $ | ||||||
| Cost of revenue | ||||||||
| Gross profit | ||||||||
| Selling expense | ||||||||
| General and administrative expense | ||||||||
| (Reversal of) provision of allowance for expected credit loss on accounts receivable | ( | ) | ||||||
| Provision of allowance for expected credit loss on loan receivable | - | |||||||
| Operating loss | ( | ) | ( | ) | ||||
| Other income (expense) | ||||||||
| Other income, net | ||||||||
| Interest expense | ( | ) | ( | ) | ||||
| Loss before income tax | ( | ) | ( | ) | ||||
| Income tax expense | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
F-40
QUANOME TECHNOLOGIES, INC. (FORMERLY KNOWN AS LAKESIDE HOLDING LIMITED)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 21 — COMMITMENTS AND CONTINGENCIES
Contractual Commitments
As of September 30, 2026, the Company’s contractual obligations consist of the following:
| Contractual Obligations | Total | Less than 1 year | 1 – 3 years | 3 – 5 years | More than 5 years | |||||||||||||||
| Operating lease obligations | $ | $ | $ | $ | — | |||||||||||||||
| Capital Expenditure Commitments (1) | — | — | — | |||||||||||||||||
| Borrowing from a related party | ||||||||||||||||||||
| Vehicle loans | — | |||||||||||||||||||
| Total | $ | $ | $ | $ | — | |||||||||||||||
Note (1):
As of September 30, 2026, the remaining contractual commitments under these agreements amounted to approximately $
The timing and settlement of these commitments are subject to the terms and conditions of the respective purchase agreements.
Contingencies
The Company may be involved in certain legal proceedings, claims and disputes arising from the commercial operations, which, in general, are subject to uncertainties and in which the outcomes are not predictable. The Company determines whether an estimated loss from a contingency should be accrued by assessing whether a loss is deemed probable and can be reasonably estimated. Although the Company can give no assurances about the resolution of pending claims, litigation or other disputes and the effect such outcomes may have on the Company, the Company believes that any ultimate liability resulting from the outcome of such proceedings, to the extent not otherwise provided or covered by insurance, will not have a material adverse effect on the Company’s unaudited condensed consolidated financial position or results of operations or liquidity as of September 30, 2026.
F-41
QUANOME TECHNOLOGIES, INC. (FORMERLY KNOWN AS LAKESIDE HOLDING LIMITED)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 22 — SUBSEQUENT EVENTS
The Company evaluated all events and transactions that occurred after September 30, 2026 up through the date the unaudited condensed consolidated financial statements were issued, and unless disclosed below, there are not any material subsequent events that require disclosure in these unaudited condensed consolidated financial statements.
Customer Agreement and Receipt of Prepayment
On September 29, 2026, XDT Infrastructure I, LLC (“XDT”), an indirect wholly-owned subsidiary of the Company, entered into an enterprise customer agreement to provide dedicated AI computing capacity and related managed infrastructure services. The initial customer order has a term of
Subsequent to September 30, 2026, XDT received an initial customer prepayment of $
At-the-Market Offering Agreement
On October 21, 2026, the Company entered into an At-the-Market Offering Agreement (the “ATM Agreement”) with Maxim Group LLC (the “Agent”), pursuant to which the Company may offer and sell shares of its common stock, par value $
Stock Purchase Agreement with QAI Labs Ltd.
On November 4, 2026, the Company entered into a Stock Purchase Agreement (the “Agreement”) with QAI Labs Ltd. (“QAI”), a Delaware corporation, pursuant to which the Company agreed to acquire
The completion of the transaction is subject to customary closing conditions, including obtaining required regulatory and third-party approvals, compliance with applicable Nasdaq listing requirements, the accuracy of representations and warranties, and the fulfillment of certain contractual obligations. The Agreement may be terminated by either party under certain circumstances, including if the transaction is not completed by December 31, 2026, unless otherwise agreed upon by the parties.
As of the date of issuance of these unaudited condensed consolidated financial statements, the transaction had not been consummated, and no shares had been issued in connection with the Agreement.
F-42
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and the related notes included elsewhere in this Quarterly Report on Form 10-Q, as well as our audited consolidated financial statements and related notes included in our Annual Report on Form 10-K for the fiscal year ended June 30, 2026. In addition to historical consolidated financial information, the following discussion contains forward-looking statements that reflect our plans, estimates, and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. All amounts included herein with respect to the three months ended September 30, 2026 and 2025 are derived from our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q. These financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) applicable to interim financial reporting.
Overview
Our business currently consists of three principal areas of focus: (i) our established, revenue-generating pharmaceutical distribution operations through Hupan Pharmaceutical; (ii) our recently initiated AI computing infrastructure business through our U.S. subsidiaries, focused on providing dedicated AI compute capacity and managed inference services; and (iii) our strategic focus on quantum-related and certain other advanced technology activities, which remains in the development and evaluation stage and has not generated revenue as of the date of this Report.
Prior to February 12, 2026, in addition to engaging in the distribution of pharmaceutical products through Hupan Pharmaceutical (Hubei) Co., Ltd. (“Hupan Pharmaceutical”), we also operated as a U.S.-based integrated cross-border supply chain solutions provider with a strategic focus on the Asian market. On February 12, 2026, we transferred the operations of American Bear Logistics Corp. (“ABL Chicago”) to an unrelated third party, which obtained operational control and substantially all economic interests associated with the business. Following the transfer, we ceased substantive involvement in ABL Chicago’s cross-border freight forwarding and logistics business. The disposal represents a strategic shift in our operations and allows management to further streamline resources and focus on the development and expansion of our pharmaceutical distribution business.
Our continuing operations are focused on the distribution of pharmaceutical products in China through Hupan Pharmaceutical. Revenue from continuing pharmaceutical operations was primarily derived from selling infusion products, foods for special medical purposes, and specialty pharmaceuticals to pharmaceutical distributors and other healthcare providers.
Beginning in September 2026, we commenced activities relating to the provision of artificial intelligence compute capacity and managed inference services through our indirectly wholly owned subsidiary, XDT Infrastructure I, LLC, a Delaware limited liability company (“XDT”). Under this business model, XDT procures, owns and operates servers and related computing infrastructure for its own account and makes computing capacity available to customers as a service. Capacity allocated to a customer is logically and operationally segregated from capacity allocated to other customers, with the level of segregation depending on the applicable customer arrangement. Customers may specify the artificial intelligence models to be deployed on the capacity allocated to them, subject to technical compatibility, licensing and other applicable requirements. XDT’s role is primarily to provide and operate the underlying computing infrastructure and managed inference environment. As of the date of this Report, the Company has entered into agreements to purchase 64 servers designed for high-performance artificial intelligence computing workloads. The Company has entered into arrangements relating to infrastructure procurement, colocation services and related operational capabilities, as well as a customer service agreement under which the commencement of services remains subject to the satisfaction of certain conditions. The Company is evaluating additional customer opportunities, negotiating capacity arrangements, and expanding its technical team and infrastructure capabilities. The Company currently has no plans to develop or train proprietary AI models and does not use customer-provided content to train models unless separately authorized by the applicable customer. The business remains at an early stage, and the Company intends to expand its customer base and computing infrastructure capabilities as the business develops.
1
Separately, the Company is evaluating opportunities to reposition its business from traditional pharmaceutical distribution services toward quantum-enabled artificial intelligence and post-quantum cryptography. The Company intends to conduct these activities through its subsidiary, Quantum Nexus Technologies Ltd. (“Quantum Nexus”), a Cayman Islands exempted company incorporated in May 2026. As part of this strategic initiative, the Company expects to develop computational capabilities through Quantum Nexus that may have applications in therapeutic discovery. The Company may also pursue collaborations, acquisitions or other strategic transactions involving laboratories and research teams engaged in therapeutic discovery and clinical research. As of the date of this Report, the Company has not entered into any definitive agreement with respect to any such transaction, and there can be no assurance that any transaction will be consummated or, if consummated, as to its timing or terms. As of the date of this Report, the Company has not generated any revenue from these activities.
The Company continually evaluates potential opportunities to expand and diversify its business operations. Smart Reserve Holding LTD and Smart Reserve Inc were formed in connection with the Company’s preliminary evaluation of potential opportunities relating to digital asset business activities. As of the date of this Report, the Company has not commenced any such business and has not adopted any concrete operational plan relating thereto. Any future expansion initiatives may be affected by factors including market conditions, capital availability, regulatory developments, operational execution, technological requirements, and management resources.
The Company’s results of operations for the period reflect the performance of its continuing pharmaceutical distribution business, and accordingly, prior period results have been recast to present the disposed business as discontinued operations where applicable. During the period, the Company also initiated preliminary activities related to the development of its AI computing infrastructure business, including making prepayment for the procurement of GPU servers designed for high-performance artificial intelligence computing workloads, and engaging in active negotiations with potential customers. Management anticipates that the AI computing infrastructure business will begin generating revenue in the second or third quarter of fiscal 2027, subject to the successful deployment of the required infrastructure and the execution of customer agreements. Management evaluates the performance of the continuing operations based on revenue growth, gross margin, operating efficiency, and working capital, while also monitoring the level of investment and operating expenditures associated with the development of its new business initiatives.
Key Factors Affecting Our Results of Operations
We believe the most significant factors that affect our business and results of operations include the following:
Regulatory Environment in China
The pharmaceutical industry in China is subject to extensive government regulation, including pricing controls, tendering processes, and reimbursement policies. Government initiatives, such as centralized procurement programs and healthcare reforms, may affect product pricing, sales volumes, and margin levels.
Supplier and Manufacturer Relationships
The Company relies on relationships with pharmaceutical manufacturers and suppliers for product sourcing. Changes in supply terms, pricing arrangements, or product availability may impact revenue and gross margins.
Customer Concentration and Demand
A significant portion of the Company’s sales is generated from large distributors. Purchasing patterns, tender cycles, and changes in customer demand or procurement policies can lead to fluctuations in revenue. During the three months ended September 30, 2026, we generated revenue from the distribution of pharmaceutical products to 23 customers, of which 4 customers accounted for more than 10% of the revenue.
2
Pricing Pressure and Competition
The Company operates in a competitive market with pressure from both domestic and international pharmaceutical distributors. Competitive pricing dynamics and participation in government bidding processes may compress margins.
Product types and composition
During the three months ended September 30, 2026 and 2025, the pharmaceutical products we distribute mainly consist of infusion drugs, specialty foods, and therapeutic drugs. The profitability level of different products varies, and the proportion of various products affects our gross profit level.
Accounts receivable collection
The current payment term provided by us to our main customers is between 0-90 days, while the payment term from the supplier is 60 days. There is also a situation of prepaying the supplier. If the accounts receivable cannot be collected in a timely manner or there are identifiable uncollectible balances, our cash flow from operating activities may be negatively affected.
AI Infrastructure Investment and Commercialization
During the period, the Company began investing in and developing its artificial intelligence infrastructure and managed inference business, including the procurement and deployment of GPU servers and related computing infrastructure and the development of related operational and technical capabilities. This business had not generated revenue during the period, nor had the Company incurred any related operating costs or expenses, other than equipment prepayments. Accordingly, these activities had no impact on the Company’s results of operations for the period. Management anticipates that the business will begin generating revenue in the second or third quarter of fiscal 2027, subject to the successful procurement and deployment of the required infrastructure and the execution of customer agreements. The future impact of this business on our results of operations will depend on, among other things, our ability to complete deployment, attract and retain customers, establish commercially viable pricing and service arrangements, manage infrastructure and operating costs and comply with applicable regulatory requirements.
Foreign Currency Fluctuations
As the Company operates in China while reporting in United States Dollar (“USD”), fluctuations in foreign exchange rates, particularly between the Renminbi and the reporting currency, may impact reported revenue and profitability.
Key Components of Results of Operations
Revenues. We generate revenues primarily from the distribution of pharmaceutical and medical products since December 2024. We order from the manufacturers, receive and carry the products at a designated warehouse, and deliver the products to the customers’ warehouses or designated locations.
Cost of Revenues. Our cost of revenues from the distribution of pharmaceutical and medical products comprises cost of pharmaceutical products from manufacturers, less discount and rebate.
Selling Expenses. Our selling expenses primarily include salaries, marketing expense of a system, entertainment expenses and traveling expense for sales team engaged in developing potential customers and maintaining customer relationships, as well as transportation costs for selling pharmaceutical products.
General and Administrative Expenses. Our general and administrative expenses primarily include salaries and staff benefits, repair and maintenance expenses, depreciation on property and equipment, amortization on intangible assets, lease expenses of office premises, travelling and entertainment expenses, bank charges, legal and professional fees, insurance expenses and other office expenses.
Other Income. Our other income primarily consists of interest income in connection with a third-party loan.
3
Interest Expenses. Our interest expenses primarily consist of interest expenses on outstanding borrowings and other financing arrangements.
Income Tax Expenses. Our income tax expenses consist primarily of PRC enterprise income tax.
Results of Operations
Continuing Operation
Our continuing operations are focused on the distribution of pharmaceutical products in China. Revenue from continuing pharmaceutical operations was primarily derived from infusion products, specialty prescription drugs, and medical nutrition products. The Company operates within a highly regulated healthcare environment and generates revenue through sales to hospitals through agents, and other healthcare providers.
Discontinued Operation
ABL Chicago is a U.S.-based integrated cross-border supply chain solution provider with a strategic focus on the Asian market, including China. We primarily provide customized cross-border ocean freight solutions and airfreight solutions in the U.S. that specifically cater to our customers’ requirements and needs in transporting goods into the U.S. We offer a wide variety of integrated services under our cross-border ocean freight solutions and cross-border airfreight solutions, including (i) cross-border freight consolidation and forwarding services, (ii) customs clearance services, (iii) warehousing and distribution services, and (iv) U.S. domestic ground transportation services.
On February 12, 2026, the sale of 100% of the issued and outstanding shares of ABL Chicago was duly approved and adopted by the Company’s shareholders. Accordingly, the Company consummated the transfer of the ABL Chicago business.
The following table summarizes the results of condensed consolidated statements of operations and comprehensive loss for the three months ended September 30, 2026 and 2025 in U.S. dollars.
| For the Three Months Ended September 30, | ||||||||||||||||||||||||
| 2026 | 2025 | |||||||||||||||||||||||
| Amount | As % of revenue | Amount | As % of revenue | Amount Increase (Decrease) | Percentage Increase (Decrease) | |||||||||||||||||||
| (unaudited) | (unaudited) | |||||||||||||||||||||||
| Revenue | $ | 2,048,083 | 100.0 | % | $ | 1,338,015 | 100.0 | % | $ | 710,068 | 53.1 | % | ||||||||||||
| Cost of revenue | 949,432 | 46.4 | % | 790,770 | 59.1 | % | 158,662 | 20.1 | % | |||||||||||||||
| Gross profit | 1,098,651 | 53.6 | % | 547,245 | 40.9 | % | 551,406 | 100.8 | % | |||||||||||||||
| Operating expenses: | ||||||||||||||||||||||||
| Selling expenses | 266,441 | 13.0 | % | 189,411 | 14.2 | % | 77,030 | 40.7 | % | |||||||||||||||
| General and administrative expenses | 1,465,397 | 71.5 | % | 933,459 | 69.8 | % | 531,938 | 57.0 | % | |||||||||||||||
| (Reversal of) provision of allowance for expected credit loss on accounts receivable | (7,656 | ) | (0.4 | )% | 66,027 | 4.9 | % | (73,683 | ) | (111.6 | )% | |||||||||||||
| Provision of allowance for expected credit loss on loan receivable | 10,662 | 0.5 | % | - | - | 10,662 | N/A | |||||||||||||||||
| Total operating expenses | 1,734,844 | 84.7 | % | 1,188,897 | 88.9 | % | 545,947 | 45.9 | % | |||||||||||||||
| Loss from operations | (636,193 | ) | (31.1 | )% | (641,652 | ) | (48.0 | )% | 5,459 | (0.9 | )% | |||||||||||||
| Other income (expense) | ||||||||||||||||||||||||
| Other income, net | 92,469 | 4.5 | % | 60,612 | 4.5 | % | 31,857 | 52.6 | % | |||||||||||||||
| Interest expense | (5,285 | ) | (0.3 | )% | (84,568 | ) | (6.3 | )% | 79,283 | (93.8 | )% | |||||||||||||
| Total other income (expense) | 87,184 | 4.3 | % | (23,956 | ) | (1.8 | )% | 111,140 | (463.9 | )% | ||||||||||||||
| Loss before income taxes | (549,009 | ) | (26.8 | )% | (665,608 | ) | (49.7 | )% | 116,599 | (17.5 | )% | |||||||||||||
| Income tax expense | 115,261 | 5.6 | % | 35,990 | 2.7 | % | 79,271 | 220.3 | % | |||||||||||||||
| Net loss from continuing operations | (664,270 | ) | (32.4 | )% | (701,598 | ) | (52.4 | )% | 37,328 | (5.3 | )% | |||||||||||||
| Net loss from discontinued operation, net of tax provision | - | - | (655,618 | ) | (49.0 | )% | 655,618 | (100.0 | )% | |||||||||||||||
| Net loss | $ | (664,270 | ) | (32.4 | )% | $ | (1,357,216 | ) | (101.4 | )% | $ | 692,946 | (51.1 | )% | ||||||||||
4
For the Three Months Ended September 30, 2026 Compared to the Three Months Ended September 30, 2025
The following table summarizes our unaudited condensed consolidated results of operations and percentages of certain items in relation to total revenues for the three months ended September 30, 2026 and 2025, and provides information regarding the dollar and percentage increase or (decrease) during such periods. The operating results in any historical period are not necessarily indicative of the results that may be expected for any future period.
| For the Three Months Ended September 30, | ||||||||||||||||||||||||
| 2026 | 2025 | |||||||||||||||||||||||
| Amount | % of total Revenues | Amount | % of total Revenues | Amount Increase (Decrease) | Percentage Increase (Decrease) | |||||||||||||||||||
| Revenue | $ | 2,048,083 | 100.0 | % | $ | 1,338,015 | 100.0 | % | $ | 710,068 | 53.1 | % | ||||||||||||
| Cost of revenue | 949,432 | 46.4 | % | 790,770 | 59.1 | % | 158,662 | 20.1 | % | |||||||||||||||
| Gross profit | $ | 1,098,651 | 53.6 | % | $ | 547,245 | 40.9 | % | $ | 551,406 | 100.8 | % | ||||||||||||
Revenues
Our revenue increased by approximately $0.7 million, or 53.1%, from approximately $1.3 million for the three months ended September 30, 2025 to approximately $2.0 million for the three months ended September 30, 2026. The increase was primarily attributable to higher sales of infusion products and an increase in the number of active customers from 8 to 16.
Infusion products accounted for approximately 97.7% and 88.8% of pharmaceutical distribution revenue for the three months ended September 30, 2026 and 2025, respectively. Revenue from infusion products increased by approximately $0.8 million, from approximately $1.2 million for the three months ended September 30, 2025 to approximately $2.0 million for the three months ended September 30, 2026. The increase was primarily driven by higher sales volumes and the acquisition of new customers.
Cost of Revenues and Gross Profit
Cost of revenue increased by approximately $0.2 million, or 20.1%, from approximately $0.8 million for the three months ended September 30, 2025 to approximately $1.0 million for the three months ended September 30, 2026. The increase was primarily driven by higher sales volume as the Company continued to expand its pharmaceutical distribution operations, partially offset by increased purchase rebates from suppliers.
Gross profit margin increased from approximately 40.9% for the three months ended September 30, 2025 to approximately 53.6% for the three months ended September 30, 2026. The increase in gross margin was primarily attributable to higher purchase rebates received from suppliers during the current period. Under the supplier agreements effective from 2026, purchase rebates are calculated based on the volume of sales to end customers, whereas under the 2025 arrangements, rebates were determined at the suppliers’ discretion. For the three months ended September 30, 2026, the Company recognized purchase rebates of $310,023.
Selling Expenses
Our selling expenses increased by $77,030, or 40.7%, from $189,411 for the three months ended September 30, 2025 to $266,441 for the three months ended September 30, 2026. The increase primarily reflected higher warehousing and logistics expenses, market research fees, and customer maintenance expenses, partially offset by lower payroll expenses.
General and Administrative Expenses
Our general and administrative expenses increased by approximately $0.5 million, or 57.0%, from approximately $0.9 million for the three months ended September 30, 2025, to approximately $1.5 million for the three months ended September 30, 2026. The increase was mainly attributable to higher professional fees.
Our professional fees increased by approximately $0.7 million, or 115.4%, from approximately $0.5 million for the three months ended September 30, 2025, to approximately $1.2 million for the three months ended September 30, 2026. Our professional fees represented 80.3% and 58.5% of our total general and administrative expenses for the three months ended September 30, 2026 and 2025, respectively. The increase was primarily due to higher amortization of prepaid share-based advisory and consulting expenses, reflecting a full quarter of expense recognition for certain consulting arrangements initiated during fiscal year 2026. These expenses included external support for market assessments, financial and operational due diligence, and the development of long-term strategic plans to support the Company’s future growth.
5
Provision of allowance for expected credit loss on loan receivable
During the three months ended September 30, 2026, the Company recognized a provision for an expected credit loss of approximately $10,662 on loans to third parties. The provision was determined based on management’s assessment of the borrowers’ creditworthiness, repayment history, current financial condition, and other relevant economic factors. The Company will continue to monitor the collectability of these loans and adjust its expected credit loss estimates as additional information becomes available.
Other Income, net
Our other income, net, increased by $31,857, or 52.6%, from $60,612 for the three months ended September 30, 2025, to $92,469 for the three months ended September 30, 2026. The increase was primarily attributable to higher interest income earned on a third-party loan.
Interest Expenses
Our interest expenses decreased by $79,283, or 93.8%, from $84,568 for the three months ended September 30, 2025, to $5,285 for the three months ended September 30, 2026. The decrease in interest expense was primarily attributable to the full repayment of the convertible debt, following which no related interest expense was incurred during the three months ended September 30, 2026.
Loss Before Income Taxes
We had a net loss before income taxes of approximately $0.5 million and approximately $0.7 million for the three months ended September 30, 2026 and 2025, respectively. The decrease in loss before income taxes was primarily attributable to higher gross profit from our pharmaceutical distribution business and an increase in other income.
Income Tax Expense
During the three months ended September 30, 2026, the Company recognized current income tax provisions of $115,261, attributable to a subsidiary that generated taxable income. No current income tax provision was recognized for subsidiaries that incurred tax losses during the period.
Based on management’s assessment of future taxable income, the Company determined that it was no longer more likely than not that sufficient future taxable income would be available to utilize the deferred tax benefits. As a result, the Company recorded a full valuation allowance against its deferred tax assets (DTAs) and did not recognize any deferred tax assets.
During the three months ended September 30, 2025, the Company recognized current income tax provisions of $57,979, attributable to a subsidiary that generated taxable income. No current income tax provision was recognized for subsidiaries that incurred tax losses during the period. The Company recognized a deferred income tax benefit of $21,989 arising from the amortization of intangible assets, resulting in a net income tax expense of $35,990 for the three months ended September 30, 2025.
Net Loss from Continuing Operation
As a result of the foregoing, our net loss from continuing operations was approximately $0.7 million and approximately $0.7 million for the three months ended September 30, 2026 and 2025, respectively.
6
Result of Discontinued Operation
On February 12, 2026, the Company disposed of its operations in ABL Chicago through a transfer to an unrelated third party. As a result, no income or loss from discontinued operations was recognized for the three months ended September 30, 2026, compared to a net loss of approximately $0.7 million for the three months ended September 30, 2025.
Liquidity and Capital Resources
Our principal liquidity requirements include funding our ongoing operating activities, meeting our working capital obligations, and supporting the development and expansion of our artificial intelligence (“AI”) computing infrastructure business. Historically, we have financed our operations and working capital requirements primarily through cash generated from operations, private placements, issuances of convertible debt, borrowings from third parties, and advances and loans from related parties.
The following table summarizes our current assets, current liabilities and working capital as of September 30, 2026, and June 30, 2026:
| As of September 30, 2026 | As of June 30, 2026 | |||||||
| Current assets | $ | 10,531,592 | $ | 11,019,992 | ||||
| Current liabilities | $ | 8,270,230 | $ | 4,486,989 | ||||
| Working capital Surplus | $ | 2,261,362 | $ | 6,533,003 | ||||
As of September 30, 2026, we had a cash balance of approximately $0.7 million. Our current assets were approximately $10.5 million, and our current liabilities were approximately $8.3 million, resulting in a current ratio of 1.3 and working capital surplus of approximately $2.3 million. Total shareholders’ equity as of September 30, 2026 was approximately $6.5 million.
As of September 30, 2026 and June 30, 2026, we had accounts receivable, net of allowances for expected credit losses, of approximately $1.4 million and approximately $1.1 million, respectively. We periodically review our accounts receivable and allowance to assess their collectability and determine whether additional allowances are necessary. For accounts receivable as of September 30, 2026 and June 30, 2026, we provided a credit loss allowance of $88,944 and $95,494, respectively.
As of September 30, 2026, our liquidity position was significantly influenced by a material loan receivable from an unaffiliated third party. The loan was made pursuant to a loan agreement dated July 3, 2025, bearing interest at 4.35% per annum with a maturity date of July 8, 2027.
As of September 30, 2026, the gross principal balance of this receivable was approximately $9.4 million, net of an allowance for expected credit losses of approximately $2.3 million. The resulting net balance represents approximately 68.1% of our total current assets, representing a significant concentration of credit risk.
Our ability to fund future operating activities and working capital requirements is partially dependent on the timely collection of the outstanding principal and interest. While we continue to monitor the counterparty’s creditworthiness and currently believe they maintain the financial capacity to meet their obligations, the recorded allowance reflects our estimate of expected credit losses under the CECL (Current Expected Credit Loss) model. Any material default or significant delay in payment by this third party could adversely impact our short-term liquidity and necessitate alternative financing. There can be no assurance that the balance will be collected in full in accordance with its contractual terms.
As of September 30, 2026, the Company had entered into two purchase agreements with third-party suppliers for the acquisition of equipment with an aggregate contractual purchase price of approximately $37.6 million. The Company had made advance payments of approximately $3.8 million, which were included in prepayment, deposit and other receivable, non-current, in the accompanying unaudited condensed consolidated balance sheets.
7
As of September 30, 2026, the remaining contractual commitments under these agreements amounted to approximately $33.9 million. The timing and settlement of these commitments are subject to the terms and conditions of the respective purchase agreements. The equipment is expected to be delivered during the second quarter of fiscal year 2027. The Company expects to finance the remaining purchase commitments through a combination of customer payments, potential borrowings from a related party, and proceeds from equity financing activities, including sales under its existing at-the-market offering program and potential additional offerings, subject to market conditions and the availability of financing.
On October 21, 2026, the Company entered into an At-the-Market Offering Agreement with Maxim Group LLC, as sales agent, pursuant to which the Company may offer and sell shares of its common stock from time to time through Maxim, subject to market conditions and applicable regulatory limitations. The Company may use proceeds from sales under the ATM program, if any, to support its working capital requirements, capital expenditures and other general corporate purposes.
On October 29, 2026, subsequent to the balance sheet date, we received a customer prepayment of approximately $13.5 million in connection with an arrangement to provide dedicated AI inference services. This prepayment is expected to provide additional liquidity to support our AI computing infrastructure business and related operating requirements.
In assessing our liquidity and capital resources, management considers our cash balances, anticipated operating cash flows, expected collections of accounts and loan receivables, capital expenditure commitments, contractual obligations, and available financing arrangements.
Our future cash requirements may increase as we expand our AI computing infrastructure, acquire and deploy additional equipment, and incur operating costs associated with providing AI inference services. Our ability to satisfy future liquidity requirements will depend on several factors, including the timing of equipment deployment, the costs of fulfilling customer service contracts, the collection of outstanding receivables, the performance of our existing operations, and the availability of additional financing if required. Management will continue to monitor these factors in evaluating our working capital requirements and capital expenditure plans.
Cash Flows
The following table sets forth a summary of our cash flows from continuing operations for the periods indicated:
| For the Three Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| Net cash used in operating activities - continuing operations | $ | (2,841 | ) | $ | (2,886,862 | ) | ||
| Net cash used in investing activities - continuing operations | (3,642,599 | ) | - | |||||
| Net cash provided by financing activities - continuing operations | 3,547,137 | 2,465,321 | ||||||
| Net cash used in discontinued operation | - | (31,461 | ) | |||||
| Effect of exchange rate changes on cash | 97,976 | 36,578 | ||||||
| Net decrease in cash | (327 | ) | (416,424 | ) | ||||
| Cash, beginning of the period – continuing operation | 670,281 | 4,814,872 | ||||||
| Cash, beginning of the period – discontinued operation | - | 141,188 | ||||||
| Total cash, beginning of the period | 670,281 | 4,956,060 | ||||||
| Cash, end of the period | 669,954 | 4,539,636 | ||||||
| Less: cash and cash equivalents of discontinued operations | - | 108,839 | ||||||
| Cash, end of the period for continuing operations | $ | 669,954 | $ | 4,430,797 | ||||
8
Operating Activities - continuing operations
Net cash used in operating activities was $2,841 for the three months ended September 30, 2026, reflecting a net loss from continuing operations of $664,270, non-cash adjustments of $742,697 and a net cash outflow of $81,268 resulting from changes in working capital. Non-cash adjustments included $784,658 of stock-based compensation for consulting services, $14,264 of depreciation, $21,371 of amortization of intangible assets and a $10,662 provision for expected credit losses on loans receivable, offset by a $7,656 reversal of allowance for expected credit loss on accounts receivable, and $90,172 of uncollected interest income from a third-party loan. Changes in working capital mainly reflected cash outflows of $244,419 from accounts receivable, $323,107 from accrued liabilities and other payables, $199,281 for prepayments, deposits and other receivables, $68,871 for contract liabilities, and interest paid on convertible note of $10,338, offset by cash inflows resulting from changes in amounts due from a related party of $501,381, primarily attributable to expenses paid by the related party on behalf of the Company, inventories of $173,944, and income tax payable of $103,975.
Net cash used in operating activities was $2,886,862 for the three months ended September 30, 2025, including net loss from continuing operations of $701,598, adjusted for non-cash items of $473,175 and changes in working capital of $2,658,439. The non-cash items primarily included $359,239 stock-based compensation for consulting expenses, $28,887 straight-line lease expense of operating leases, $10,599 depreciation expense, $21,371 amortization of intangible asset, $69,602 amortization of discount and bond issuance cost, $66,027 provision of allowance for expected credit loss on accounts receivable, $60,561 uncollected interest income from a third-party loan and a decrease of $21,989 from deferred tax liabilities. The adjustments for changes in working capital mainly included cash inflows of $166,396 from accrued expense and other payable, $121,571 from refund liabilities, $61,133 from right of return asset, $45,704 from income tax payable, $182,343 from accounts payable and $18,175 from contract liabilities, partially offset by outflows of $269,269 from accounts receivable, $35,452 from inventories, $2,953,966 from prepayment, deposit and other receivable, and 46,353 from operating lease liabilities.
Net cash used in operating activities decreased by $2,884,021 for the three months ended September 30, 2026, compared to the corresponding period in 2025, which was primarily attributable to a decrease in cash used for working capital, reflecting lower prepayments and deposits made during the current period.
Investing Activities - continuing operations
Net cash used in investing activities was $3,642,599 and nil for the three months ended September 30, 2026 and 2025, respectively. Net cash used in investing activities for the three months ended September 30, 2026 was primarily attributable to the purchase of furniture and equipment of $3,763,200, principally relating to servers and related computing infrastructure for the Company’s artificial intelligence compute capacity business, partially offset by $120,601 received from a third party in respect of a loan receivable. There were no significant investing activities for the three months ended September 30, 2025.
Financing Activities - continuing operations
Net cash provided by financing activities was $3,547,137 and $2,465,321 for the three months ended September 30, 2026 and 2025, respectively. The increase of $1,081,816 was primarily due to proceeds from a related-party borrowing during the three months ended September 30, 2026. During the three months ended September 30, 2026, we generated cash inflows of $3,799,980 from a loan from a related party, partially offset by principal repayments of $74,747 on convertible debt and $173,167 in repayments on other loans. During the three months ended September 30, 2025, we generated cash inflows of $3,000,000 from a private placement, partially offset by $334,346 in principal repayments of convertible debt and $181,166 in advances to a third party.
Cash Flows from Discontinued Operations
There were no cash flows from discontinued operations for the three months ended September 30, 2026. For the three months ended September 30, 2025, discontinued operations used $1,129,656 in operating activities and $108,800 in investing activities, and provided $1,206,995 in financing activities, resulting in a net cash outflow of $31,461. See Note 17, “Discontinued Operations,” to the unaudited condensed consolidated financial statements for additional information.
9
Capital Expenditure
Our capital expenditures are incurred primarily in connection with the purchase of fixed assets, including machinery and equipment, furniture and fixtures, leasehold improvement and vehicles. Our capital expenditures amounted to $3,763,200 and nil for the three months ended September 30, 2026 and 2025, respectively.
We expect that our capital expenditures will increase in the future as our business continues to develop and expand. We intend to fund our future capital expenditures with our existing cash balance, proceeds from loans and issuance of convertible debts and private placement offering.
Critical Accounting Policies and Estimates
We prepare our consolidated financial statements in conformity with U.S. GAAP, which requires us to make judgments, estimates and assumptions that affect our reported amounts of assets, liabilities, revenue, costs and expenses, and any related disclosures. Actual results could materially differ from those estimates. Critical accounting policy is both material to the presentation of financial statements and requires management to make difficult, subjective or complex judgments that could have a material effect on financial condition or results of operations. Accounting estimates and assumptions may become critical when they are material due to the levels of subjectivity and judgment necessary to account for highly uncertain matters or the susceptibility of such matters to change, and that have a material impact on financial condition or operating performance.
Critical accounting estimates are estimates that require us to make assumptions about matters that were highly uncertain at the time the accounting estimate were made and if different estimates that we reasonably could have used in the current period, or changes in the accounting estimate that are reasonably likely to occur from period to period, have a material impact on the presentation of our financial condition, changes in financial condition or results of operations. The management of the Company believes the following critical accounting estimate is the most significantly affected by judgments and assumptions used in the preparation of our consolidated financial statements.
Allowance of expected credit losses on loan receivable from third parties
The Company accounts for its allowance for credit losses on loan receivables in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 326, Financial Instruments—Credit Losses (“ASC 326”). The Company assesses the credit risk of its third-party loan receivables at each reporting date to ensure that the allowance reflects management’s current estimate of expected credit losses over the contractual life of the instrument.
The measurement of the allowance for expected credit losses is primarily determined using a Probability of Default (“PD”) and Loss Given Default (“LGD”) methodology. This assessment considers whether the borrower meets its contractual obligations and involves an evaluation of the borrower’s historical performance, current financial condition, and the value of any underlying collateral.
10
The PD × LGD model includes various assumptions, including the selection of forward-looking macroeconomic forecasts (such as interest rate environments), the borrower’s credit rating, and estimated recovery rates. This assessment, which requires the use of significant professional judgment, is conducted at the time of loan inception and as of each subsequent quarterly period end date while the loan is outstanding. These assumptions reflect management’s best estimates based on current and supportable information, but they involve inherent uncertainties based on economic and market conditions generally outside of the Company’s control. Changes in these estimates are recognized in the unaudited condensed Consolidated Statements of Loss and Comprehensive Loss in the period in which they occur.
Refer to Notes 2 to the consolidated financial statements included in this report for further discussion of our significant accounting policies and the effect on our consolidated financial statements.
Recent Accounting Pronouncements
The Company considers the applicability and impact of all accounting standards updates (“ASUs”). Management periodically reviews new accounting standards that are issued, see “Note 2 - Summary Of Significant Accounting Policies” to the consolidated financial statements.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and are not required to provide the information otherwise required under this item.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our chief executive officer and chief financial officer, has performed an evaluation of the effectiveness of our disclosure controls and procedures (as defined under Rules 13a-15(e) and 15d-15(e) of the Exchange Act) as of the end of the period covered by this report.
Based upon this evaluation, our management concluded that as of September 30, 2026, our disclosure controls and procedures were not effective at the reasonable assurance level due to the material weaknesses described below.
| ● | We lack adequate segregation of duties and effective risk assessment; and |
| ● | We lack sufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both the U.S. GAAP, and SEC guidelines. |
A material weakness is a deficiency, or a combination of deficiencies, within the meaning of PCAOB Auditing Standard AS2201, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis. We plan to address the weaknesses identified above by implementing the following measures:
| (i) | Continuously hiring additional accounting staffs with comprehensive knowledge of U.S. GAAP and SEC reporting requirements; |
| (ii) | Designing and implementing formal procedures and controls supporting the Company’s period-end financial reporting process, such as controls over the preparation and review of account reconciliations and disclosures in the consolidated financial statements; and |
| (iii) | Ameliorating our internal audit to assist with assessment of Sarbanes-Oxley compliance requirements and improvement of internal controls related to financial reporting. |
Changes in Internal Control over Financial Reporting
During the most recent fiscal quarter, there has not been any change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
11
PART II. OTHER INFORMATION
Item 1. Legal Proceedings
From time to time, we may be subject to legal proceedings, investigations and claims incidental to the conduct of our business. We are currently not a party to, nor are we aware of, any legal proceedings, investigations or claims which, in the opinion of our management, are likely to have a material adverse effect on our business, financial condition or results of operations.
Item 1A. Risk Factors
We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and are not required to provide the information otherwise required under this item.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
None.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
None.
Item 5. Other Information
12
Item 6. Exhibits
The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q for the quarter ended September 30, 2026.
| Exhibit Number | Description | |
| 3.1 | Certificate of Amendment to the Articles of Incorporation of the Registrant, dated July 2, 2026 (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K (File No. 001-42140), filed with the SEC on July 7, 2026). | |
| 3.2 | Amended and Restated Articles of Incorporation of the Registrant (incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K (File No. 001-42140), filed with the SEC on July 7, 2026). | |
| 3.3 | Certificate of Amendment to the Articles of Incorporation of the Registrant dated July 31,2026 (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K (File No. 001-42140), filed with the SEC on August 4, 2026). | |
| 3.4 | Bylaws of the Registrant (incorporated by reference to Exhibit 3.3 to the Registration Statement on Form S-1 (File No. 333-278416), filed with the SEC on April 1, 2024). | |
| 3.5 | Amendment No.1 to the Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K (File No. 001-42140), filed with the SEC on August 4, 2026). | |
| 4.1 | Form of Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the Amendment No. 1 to Registration Statement on Form S-3 (File No. 333-297324), filed with the SEC on August 5, 2026). | |
| 4.2 | Form of Indenture, between the Registrant and one or more trustees to be named (incorporated by reference to Exhibit 4.3 to the Amendment No. 1 to Registration Statement on Form S-3 (File No. 333-297324), filed with the SEC on August 5, 2026). | |
| 10.1 | At The Market Offering Agreement, dated October 21, 2026, by and between Quanome Technologies, Inc. and Maxim Group LLC. (incorporated by reference to Exhibit 1.1 to the Current Report on Form 8-K (File No. 001-42140), filed with the SEC on October 21, 2026). | |
| 10.2*+ | Revolving Loan Agreement, dated September 28, 2026, by and between Quanome Technologies, Inc. and Yang Li. | |
| 10.3*+† | Purchase and Sale Agreement and related purchase order, dated September 29, 2026, by and between Quanome Technologies, Inc. and Compal Electronics, Inc. | |
| 10.4*+ | Token Factory Master Services Agreement, a Supplemental Agreement No. 1 and a service order, dated September 29, 2026, by and between XDT Infrastructure I, LLC and XPERT SOFTWARE SOLUTIONS PTE. LTD. | |
| 31.1* | Rule 13a-14(a) / 15d-14(a) Certification of Principal Executive Officer. | |
| 31.2* | Rule 13a-14(a) / 15d-14(a) Certification of Principal Financial Officer. | |
| 32.1# | Section 1350 Certifications of Principal Executive Officer. | |
| 32.2# | Section 1350 Certifications of Principal Financial Officer. | |
| 101 | Inline XBRL Document Set for the consolidated financial statements and accompanying notes in Part I, Item 1, “Financial Statements” of this Quarterly Report on Form 10-Q. | |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |
| + | Certain portions of this exhibit have been redacted in accordance with Item 601(a)(6) of Regulation S-K. |
| † | The schedules to this agreement have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby agrees to furnish supplementally a copy of any omitted schedule to the SEC upon request. |
| * | Filed herewith. |
| # | This certification is deemed not filed for purpose of Section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act. |
13
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| QUANOME TECHNOLOGIES, INC. | ||
| Dated: November 16, 2026 | By: | /s/ Yang Li |
| Yang Li | ||
| Chief Executive Officer (Principal Executive Officer) | ||
14